US20020082513A1 - Anesthesia monitoring system based on electroencephalographic signals - Google Patents
Anesthesia monitoring system based on electroencephalographic signals Download PDFInfo
- Publication number
- US20020082513A1 US20020082513A1 US10/007,849 US784901A US2002082513A1 US 20020082513 A1 US20020082513 A1 US 20020082513A1 US 784901 A US784901 A US 784901A US 2002082513 A1 US2002082513 A1 US 2002082513A1
- Authority
- US
- United States
- Prior art keywords
- patient
- index
- psi
- artifact
- observer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4821—Determining level or depth of anaesthesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/369—Electroencephalography [EEG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/369—Electroencephalography [EEG]
- A61B5/372—Analysis of electroencephalograms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7203—Signal processing specially adapted for physiological signals or for diagnostic purposes for noise prevention, reduction or removal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7235—Details of waveform analysis
- A61B5/7264—Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7235—Details of waveform analysis
- A61B5/7253—Details of waveform analysis characterised by using transforms
- A61B5/7257—Details of waveform analysis characterised by using transforms using Fourier transforms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/01—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes specially adapted for anaesthetising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/08—Other bio-electrical signals
- A61M2230/10—Electroencephalographic signals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/60—Muscle strain, i.e. measured on the user
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
Definitions
- the current invention relates to the field of medical anesthesia. More particularly it relates to the field of electronic monitoring of patients undergoing anesthesia, especially for use during and after surgical operations.
- the invention relates more specifically to the use of electroencephalograph (EEG) signals for electronically monitoring a patient's state of awareness.
- EEG electroencephalograph
- Anesthesiology is a medical art practiced in the United States by and large by board certified physicians (anesthesiologists) and nurses (nurse anesthetists) specifically trained to administer anesthetic drugs and monitor patients under anesthesia.
- the state of patient anesthesia is attained by the controlled administration of various drugs with known anesthetic properties. These drugs cause the patient to lose consciousness, sensation, and motor control.
- the physician monitors the patient's state of awareness by means of a number of disparate clinical signs known empirically to provide useful and reliable information about the patient's state of unconsciousness.
- the patient is anesthetized prior to surgery by the specialized medical practitioner (anesthesiologist or nurse anesthetist), who administers one or more vapors or gases by inhalation or introduces anesthetic drugs intravenously.
- Volatile substances include nitrous oxide, sevoflurane, desflurane, flurane and isoflurane, and halothane.
- Intravenous anesthetics include pentothal, evipal, procaine, nitrous narcotic with propofol induction, methohexital, and etomidate.
- the anesthetic should further disable the patient's motor control so that the patient cannot move. Otherwise, the patient may exhibit involuntary (reflex) muscle movements, which can disturb the area being surgically manipulated. Prevention of movement can be accomplished by anesthetic agents acting on the central nervous system or with a blockade of the neuromuscular junction with muscle relaxants.
- the anesthesia must avoid depressing the patient's blood pressure so much as to reduce blood flow to the brain to a dangerous extent.
- 50 mm Hg for mean arterial pressure is a lower limit.
- a trained anesthesiologist or nurse anesthetist will monitor the patient's vital signs such as respiration and pulse rates, check the patient's pupil dilation, and check certain reflexes, such as the lash reflex, and other physiological signs to estimate the depth of anesthesia.
- the practitioner does not have access to all of the required clinical information or other circumstances intervene.
- the patient is draped in such a way as to make observation of some clinical indicators difficult or impossible.
- the attention of even the best practitioner can flag.
- a number of inventors have developed systems for using EEG signals, generally in combination with other signals, to monitor anesthesia, sleep, or other states on the consciousness-unconsciousness continuum.
- Kaplan et al. U.S. Pat. No. 5,813,993, issued Sep. 29, 1998, disclosed a drowsiness detection system based on EEG signals. This invention relies heavily on frequencies in EEG signals above 30 Hz. It does not use any form of norming and in addition applies an ad hoc weighted sum of inverted spectral power coefficients. Maynard, U.S. Pat. No. 5,816,247, issued Oct.
- Kangas et al. U.S. Pat. No. 5,775,330, issued Jul. 7, 1998, uses transform processing and neural net analysis to classify states of anesthesia.
- the output of the neural net could be used to produce a single index of awareness.
- all of these prior art systems either represent an unnecessary level of complexity or an absence of empirical basis or both.
- This system combines certain features of EEG signals and other features including those of evoked potentials to arrive at an estimate of the patient's state of consciousness. It specifically incorporates the use of electrocardiograph (EKG) and electromyograph (EMG) electrodes and also input from a blood pressure detector and from a respiration monitor.
- EKG electrocardiograph
- EMG electromyograph
- This prior art system also requires evoked potentials, specifically Brainstem Auditory Evoked Response (BAER) and Brainstem Somatosensory Evoked Response (BSER).
- BAER Brainstem Auditory Evoked Response
- BSER Brainstem Somatosensory Evoked Response
- Use of evoked potentials involves the use of additional disposables and a longer set-up time. Further, this system relies very heavily on self-norming and in particular on updating
- Prichep U.S. Pat. No. 5,083,571, issued Jan. 28, 1992, disclosed a significant advance in the utilization of EEG signals for diagnostic purposes.
- Prichep disclosed the use of discriminant analysis to sharpen the diagnostic capability of quantities derived from EEG signals with respect to certain well-known diagnostic categories of psychiatric illness. This work compared quantities derived from a patient with parameters derived from populations of persons thought to suffer from specific identified illnesses.
- the current invention comprises a system for using EEG signals to monitor the state of anesthesia of a patient at various stages preparatory to, during, and after administration of anesthetic and surgical operation, and in intensive care during recovery from the operation and anesthesia.
- the system comprises a headset attached to a patient, a patient module connected to the headset, apparatus for transmitting EEG signals to an analysis unit, and the analysis unit itself.
- the analysis unit further comprises a number of subsystems, but its essence is the Algorithm which processes the EEG signals into a parameter usable to estimate and/or track the patient's state of unconsciousness or consciousness while under anesthesia.
- the primary function of the analysis unit is to classify anesthetized patients according to their conscious state, as determined from an analysis of volunteer data using the OAA/S scale.
- the version of this scale used in this invention is: Modified Observer's Assessment of Alertness/Sedation Scale Response Score Responds readily to name spoken in a normal tone 5 Lethargic response to name spoken in a normal tone 4 Responds only after name is called loudly and/or repeatedly 3 Responds only after mild shaking or prodding 2 Responds only to noxious stimulus and not to mild shaking or 1 prodding Does not respond to noxious stimulus 0 Burst Suppression ⁇ 1
- the design of the analysis unit is based on the Multiple Observer Derived Measurement Model depicted in FIG. 1.
- An observer is a thread of execution and logic, an algorithm, which processes a stream of data and generates a measure of a characteristic(s) identified within the data stream. The principle is that is easier to construct individual observers tuned to specific characteristics in the data stream, than to create one observer that is tuned to classify an ensemble of characteristics in the data stream.
- Observers 3 are classifier functions that detect signatures within the information. These signatures may be in the time domain, frequency domain, or a combination of the two domains. By tuning observers to specific signatures, selective filtering can be employed to improve the accuracy and latency of an observer. What may be noise to one observer may be critical information to another. This selective filtering increases the overall utilization of the acquired physiological information and thereby improving the performance of the final derived measure.
- An Observer Mediator 4 is responsible for logically combining these individual observations in to the single Derived Parameter.
- the Observer Mediator can weigh the individual observations by monitoring each observer's input signal quality and the context of the observation based on the patient state. The patient state is derived from the behavior of the derived parameter over time and this is fed back to the Observer Mediator. Functionally, either on demand or on a periodic basis, the Observer Mediator polls the Observers and based on patient state and the ‘quality’ of the individual observations, combines the observations into a single derived measure.
- the Derived Parameter may be enhanced in sensitivity or scope by either further tuning of established Observers or adding additional Observers.
- the primary output of the PSA 4000 algorithm is a single derived parameter called the Patient State Index (PSI) that maps to the OAA/S scale independent of anesthetic agent.
- PSI Patient State Index
- FIG. 2 The implementation of the Multiple Observer Model for this measure of state of consciousness, the PSI, is shown in FIG. 2.
- EEG electroencephalograph
- These raw EEG signals are filtered and decimated to reduce external noise and to satisfy data sampling rate (Nyquist) requirements.
- the processing analyzes information in the 0.5 Hz to 50 Hz frequency range.
- the sample data streams are divided into two primary streams: the FP1 channel is separately processed by the Beta5 Observer, all channels [FP1, FPz′, Pz, Cz] are processed by an ensemble of signal morphological classifiers 13 (artifact detectors).
- the Beta5 Observer's signal quality can be assessed.
- the FP1's signal quality is combined with Beta5 analysis 9 and evaluation 11 by the Beta5 Observer and propagated to the Observation Mediator.
- the outputs of the Signal Morphology Classifiers are four artifact free EEG data streams and a declaration of the types of artifacts detected.
- the Eyeblink Observer 19 is notified of the number and types of eyeblinks detected in the four EEG channels.
- the Suppression Observer 20 is notified whether EEG suppression has been detected over the last time period.
- the artifact free EEG data is further processed by the PSI Discriminant Observer 18 , which performs a more complex multiple component analysis that serves as the foundation of the consciousness algorithm.
- the four observations: Beta5, PSI Discriminant, Eyeblink and Suppression) are propagated to the Observation Mediator 25 .
- the Mediator combines these observations with measures of signal quality and appropriateness of observations based on patient state into an update of the Patient State Index and the associated trend.
- the time course of the PSI is monitored and logic is applied to assess the patient's state and this information is fed back to the Observation Mediator. It is through the use of this Multiple Observer Model that a clinically functional measure of state of consciousness is realized.
- the output of the Algorithm is a set of four processed parameters calculated every 2.5 seconds (each 2.5 second block is referred to as an epoch). These are the main output parameter, i.e., the Patient State Index (PSI); the Suppression Ratio (SR); the EMG index (EMG); and the Artifact Index (ART).
- PSI Patient State Index
- SR Suppression Ratio
- EMG EMG index
- ART Artifact Index
- the measures in addition to the PSI provide additional information to the instrument operator on either specific aspects of the patient state or data quality. These measures are shown in FIG. 2 to be directed to the User Interface.
- the Artifact Index is a measure of signal quality.
- the SR-Ratio is the percentage of time in the last minute the patient's EEG has been suppressed.
- the Beta2 component measure is related to the degree of muscle activity (EMG) detected.
- EMG muscle activity
- the outputs of this multiple observer based PSA 4000 algorithm is a periodic update of: the Patient State Index (the primary derived parameter), the Artifact Index, the Suppression Ratio and a measure of EMG activity.
- the Patient State Index 164 the primary indicator of patient level of awareness, is developed to characterize the relative state of consciousness of an anesthetized patient.
- the Algorithm outputs a periodic update of this primary parameter.
- the Algorithm provides for upper and lower thresholds of this parameter within which the patient will be said to be in an appropriate level of unconsciousness for surgery. (Other levels may be appropriate for other conditions such as intensive care sedation.)
- the PSI range is defined to be from 0 to 100, with higher values indicating a higher level of consciousness or awareness.
- the Suppression Ratio 162 is an indicator of the relative amount of time that the patient's EEG waveforms exhibit a characteristic Burst Suppression pattern.
- the Burst Suppression pattern is accepted to be an indicator of deep levels of unconsciousness under sedation. In certain situations of traumatic head injury, for example, it is necessary to reduce the brain's need for oxygen by putting the patient into a drug induced (barbiturate) coma. This brain state is observed in the EEG as Burst Suppression. For most surgical procedures, burst suppression is considered an inappropriately deep level of sedation where the anesthesiologist would normally reduce drug flow rates accordingly.
- the Suppression Ratio is the percentage of epochs (2.5-second epochs) in the last one minute that have been declared as Suppressed Epochs.
- the EMG Index 163 is an indicator of muscle activity. Under certain conditions, an EMG response may be interpreted as an indicator of the patient's response to pain or stress.
- the anesthesiologist's action would depend upon the conditions present when the EMG response occurs, as EMG is a normal indication at the end of surgery. During surgery, the anesthesiologist titrates additional hypnotic for stress or analgesic for pain accordingly.
- the EMG Index is a weighted percentage of half-epochs (over the past one minute) in which muscle activity, as measured by the power in the BETA-2 band, exceeds a threshold level. Newer epochs are weighted more heavily than the older ones.
- the Artifact Index 165 is an indicator of data quality, or of the amount of artifacts present in the data. It is also a weighted percentage (over the past one minute). Increase in the artifact index is normal during any patient movement and may be associated with the use of certain equipment such as BOVI or train-of-four when applied to the face. Poor contact impedance aggravates all sources of artifact and will require intervention by the anesthesiologist to correct poor electrode contact with the patient.
- FIG. 1 portrays the basic structure of the Multiple Observer Model.
- FIG. 2 is a more detailed illustration of the Multiple Observer Model.
- FIG. 3 shows the basic structure of the system
- FIG. 4 shows the basic logical flow of the Algorithm.
- FIG. 5 continues and supplements the logical flow diagram of the Algorithm.
- FIG. 6 shows the final stages of the logical flow of the Algorithm.
- FIG. 7 depicts the flow of information between buffers.
- the PSA Patient Interface consists of a Patient Module 42 , patient interface cable 43 , and a Patient Electrode Set 44 designed to provide a superior quality, programmable patient interface for EEG monitoring in the OR and ICU.
- the Patient Module is housed in a custom molded plastic enclosure with an integral universal-mounting bracket that facilitates attachment to an IV pole, bed sheet or rail.
- a detachable patient interface cable provides a quick connect/disconnect capability to the PSA appliance or Patient Module.
- EEG signals from the appliance are acquired with an isolated instrumentation grade, 4-channel pre-amplifier assembly and programmable multiplexed high speed A/D converter. The signal inputs are acquired referentially with reformatting provided by the Host application if necessary.
- Preamplifier optimization for EEG is standard, with EP and ECG optional by design.
- the combination of optically isolated data pathways, a low leakage/high isolation power converter and amplifiers with precise gain and band-pass matching results in greater than 120 dB CMRR.
- Calibration, Impedance Test, and Normal Operation are remotely controlled through the DSP Interface using commands generated by the Host Application.
- a full duplex connection is provided between the Patient Module and the DSP via dual optical-isolators that comply with VDE0884 for safety with extremely low leakage.
- the power converter is a UL Listed & Medical Grade. This extreme isolation results in negligible leakage currents and assures IEC601/UL2601 compliance with superior common mode performance.
- the proprietary ISA bus DSP card provides a real time interactive link between the host and patient module and manages the acquisition, calibration and impedance functions of the patient module. Balanced differential drivers are used to minimize EMI associated with serial data transmission while providing the ability to extend the link to approximately 1000 feet. Filtering and decimation of the acquired data takes place in the DSP.
- the PSA 4000 analysis unit embodies and operates by means of a complex Algorithm referred to hereafter as the PSA 4000 Algorithm.
- the system operates in three distinct modes, sometimes referred to as states, with different characteristics.
- the three states are labeled as follows: 1) Data Accumulation; 2) Awake Patient; and 3) Unconscious Patient.
- Two very specific and well-defined events cause the transition of the system among these four states. These events are labeled as: 1) Sufficient Data Accumulated ; and 2) Loss of Consciousness.
- the identification of events and the switching among the states at the occurrence of an identified event is described further below following the description of the operation of the PSA 4000 Algorithm.
- t j The time associated with a particular sample set is denoted by t j . The time resolution of the algorithm neglects the miniscule differences between time values of electrode values in a sample.
- S j S(j) The sample associated with a particular index j.
- S(t j ) The sample associated with a particular time.
- the basic operational modules of the PSA 4000 Algorithm are: EEG Data Collection, Filtering and Decimation; Artifact Detection and Signal Morphology Analysis; Eye-blink Observation; Suppression Observation; Calculation of Artifact Index; Calculation of Suppression Ratio Index; FFT Calculation; Spectral Band Decomposition; Calculation of the EMG Index; EMG Beta-5 Observation; Discriminant Observer Calculation of the Probability of Correct Classification; Observer Mediation for the PSI; and Display of the PSI, the Suppression Ratio Index, the EMG Index, and the Artifact Index.
- the patient module (PM) 42 acquires EEG data at a sampling rate of 2500 Hz.
- the sampling and processing are established to produce a frequency representation resolution of 0.25 Hz or better.
- the filtered sample is stored in the buffer as shown in FIGS. 8 and 9 and refreshed every half epoch.
- Artifact detection and analysis are performed once every sample, i.e., 250 times per second in an Artifacter Bank 103 - 108 . This analysis results in an artifact type being associated with every sample that is classified as being affected by an artifact. Artifact types are also collated on an epoch-by-epoch basis. Artifact analysis is performed only onfiltered samples. As shown in FIG. 5, after the high-pass filter, the artifact engine analyzes data on four channels for 5 kinds of artifacts:
- artifact analysis is done on a series of sample sets (sample buffers) of varying sizes.
- the magnitude, suppression, slew rate, and eye blink artifacts are checked on a buffer of 150 samples. These 150 samples (0.6 seconds) are older than the latest 312 of the 625 samples that have gone through the high-pass filter. Thus, they are identical with the newest 150 samples in the older half of the high-pass filter buffer.
- the rms deviation artifact is checked on the 2000 samples (8.0 seconds) before (older than) the latest 75 of the 150 samples that were checked for the previous artifact types.
- the magnitude of the newestfiltered sample is checked, on each of the four channels 103 . (Recall that the latest filtered sample is older than the latest sample by L1 ⁇ 2 samples.) If the magnitude of at least one of the channels exceeds a set threshold, the sample is ⁇ s ′ ⁇ ( - 1 2 ⁇ L 1 ) ⁇ > M thresh 2
- M thresh is the magnitude threshold.
- the magnitude threshold is different for different channels and is determined empirically.
- the slew rate detector 107 checks for sudden changes in the magnitude of samples. The rate of change cannot be greater than 15 ⁇ V over 20 ms. To check this, the detector obtains the largest sample and the smallest sample over the ⁇ slew samples older than s′( ⁇ 1 ⁇ 2L 1 ⁇ 1 ⁇ 2L 2 ). If the difference between sample s′( ⁇ 1 ⁇ 2L 1 ⁇ 1 ⁇ 2L 2 ) and either the largest or the smallest sample is greater than 15 ⁇ V, than a slew rate artifact is declared.
- the conditions can be expressed as: s ′ ⁇ ( - 1 2 ⁇ L 1 - 1 2 ⁇ L 2 ) - min ⁇ ( - 1 2 ⁇ L 1 - 1 2 ⁇ L 2 - ⁇ slew , - 1 2 ⁇ L 1 - 1 2 ⁇ L 2 ) > L thresh 3 max ⁇ ( - 1 2 ⁇ L 1 - 1 2 ⁇ L 2 - ⁇ slew , - 1 2 ⁇ L 1 - 1 2 ⁇ L 2 ) - s ′ ⁇ ( - 1 2 ⁇ L 1 - 1 2 ⁇ L 2 ) > L thresh 4
- L thresh is threshold for the slew rate artifact, equal to 15 ⁇ V. If either one of these conditions is satisfied, a slew rate artifact is declared.
- the conditions for eye blinks, 104 and 105 are checked only if the slew rate artifact is not detected because the slope required in a slew rate artifact is larger than the slope required for eye blinks
- the eye blink observer is mathematically similar to the slew rate detector, however, it checks for both positive and negative slopes together, i.e., it checks for EEG humps within certain parameters.
- the observer checks for the conditions on the rise (the first half of the eyeblinks).
- the artifactor checks the ⁇ EBSb samples older than sample s′( ⁇ 1 ⁇ 2L 1 ⁇ 1 ⁇ 2L 2 ) and obtains the largest and smallest samples.
- a small eye blink is declared.
- the conditions are: max ⁇ ( - 1 2 ⁇ L 1 - 1 2 ⁇ L 2 - ⁇ EBLb , - 1 2 ⁇ L 1 - 1 2 ⁇ L 2 ) - s ′ ⁇ ( - 1 2 ⁇ L 1 - 1 2 ⁇ L 2 ) > ⁇ L thresh ⁇ ⁇ ⁇ or ⁇ ⁇ AND ⁇ ⁇ or 11 s ′ ⁇ ( - 1 2 ⁇ L 1 - 1 2 ⁇ L 2 ) - min ⁇ ( - 1 2 ⁇ L 1 - 1 2 ⁇ L 2 , - 1 2 ⁇ L 1 - 1 2 ⁇ L 2 + ⁇ EBLa ) > L thresh 12 max ⁇ ( - 1 2 ⁇ L 1 - 1 2 ⁇ L 2 , - 1 2 ⁇ L 1 - 1 2 ⁇ L 2 + ⁇ EBLa ) -
- the suppression detector 109 looks at the sum of the squared deviations of samples over the latest filtered 600 milliseconds (150 samples, denoted by L 2 ) and over the latest filtered 20 milliseconds (5 samples, denoted by L 5 ).
- the sum of the squared deviations is: where j 1 andj 2 are sample indices, and No(j 1 , j 2 ) is the number of samples between these indices.
- the suppression condition is where S thresh is the threshold for the Suppression Artifact.
- the thresholds are different for the different channels and are determined empirically.
- the suppression Observer calculates a quantity called the persistent Suppression Ratio (pSR). It is defined as the percentage, over the past 2.5 minutes, of 2.5-second epochs in which a suppression artifact was detected.
- pSR persistent Suppression Ratio
- the pSR is also calculated based on 2.5-sec suppressed epoch declarations, even though 1.25-sec suppressed epoch declarations are available from the current overlapping-FFT scheme. (Recall that the connecting rule is, if one of the two 1.25-sec epochs in a 2.5-sec epoch is declared suppressed, then the 2.5-sec epoch is declared suppressed.)
- the pSR is used later in calculating the PSI from the PCC.
- the 2.5-second Artifact Index 106 is one of the four final output parameters communicated to the user of the PSA 4000.
- the Artifact Index is a time-weighted percentage of 48 overlapped epochs (1.25-second epochs) in the past one minute that were declared as artifacted epochs. The newer half-epochs are weighted more heavily than the older half-epochs.
- the Artifact Index is calculated every 1.25 seconds.
- the Suppression Ratio (SR) 143 is also one of the four final output parameters communicated to the user of the PSA 4000.
- the SR is defined as the percentage, over the past one minute, of 2.5-second epochs in which a suppression artifact was detected.
- the FFT of the time series i.e., the set of 625 samples, also called an epoch
- a Hamming Window is applied to the time series data before the calculation of every FFT (see references).
- EEG data is sliced into 2.5-second periods, called epochs, containing 625 samples each. The Fourier Transform of an epoch of EEG data is calculated.
- FFT calculations 126 , 128 are done using a 50% overlap scheme, i.e., FFT calculations are done every 1.25-seconds for data covering the last good 2.5-second period.
- band definitions are used in succeeding Algorithmic calculations 146 .
- the band definitions are given in units of Hertz (Hz).
- Hz Hertz
- TABLE 1 Band Name Band definition (Hz) ⁇ 1.5-3.5 ⁇ 3.5-7.5 ⁇ 7.5-12.5 ⁇ 12.5-25.0 ⁇ 2 25.0-50.0 ⁇ 5 35.0-50.0 tot 1.5-25.0
- the band tot spans only the bands ⁇ through ⁇ .
- the EMG Index 148 is an indicator is a time-weighted percentage of 1.25-second epochs in the past one minute that had an F 1 ⁇ 2 z-component of greater than 1.96. The newer half-epochs are weighted more heavily than the older half-epochs.
- the F 1 ⁇ 5 raw measure 126 is the power on the F 1 channel in the ⁇ 5 band.
- the F 1 ⁇ 5 Z-component is the logarithm of the raw measure, and the F 1 ⁇ 5 Z score is the population-normed Z-component.
- the F 1 ⁇ 5 index is defined as a running average of the F 1 ⁇ 5 Z-scores over the past twelve overlapped-epochs, in which the newest Z-score is limited to a maximum change of six population standard deviations from the latest running average.
- a discriminant 149 is a function of statistical variable that maximizes the separation, in the variable space, of two groups of interest. It is usually a linear combination of the statistical variables. Thus, specification of the discriminant involves both specification of the variables and their weights.
- the Raw Measures used by the discriminant observer 18 are defined by the following table: TABLE 1 Raw Measures as a combination of electrodes and bands tot ⁇ ⁇ ⁇ ⁇ ⁇ 2 FP 1 P P FP z' F P P C z P P P z P P P P
- P refers to monopolar power and F refers to mean frequency.
- the raw measures are averaged over 32 overlapped-epochs.
- the first 8 are used in calculating the PCC.
- the 9 th is used in calculating the final EMG Index output parameter.
- Z-components are obtained from the raw components by norming to a set of population means and standard deviations, which are obtained for each component from an experimental study of normative populations.
- Z scores are either linear combinations of Z components, or identical to the z components.
- the z-score set used in the PSA 4000 discriminant is: TABLE 3 Z-score set used in calculating the probability of correct classification Zscore # Definition in terms of Z-components 1 monop power (FP 1 Tot) 2 mean frequency (FP z' Tot) 3 monop power (FP z' ⁇ ) - monop power (P z ⁇ ) 4 power assymetry (FP 1 C z ⁇ 2 ) 5 relative power (P z ⁇ ) 6 monop power (FP z' ⁇ ) - monop power (C z ⁇ )
- the z-scores are linearly combined with weights such that the linear combination will maximize the separation between the two statistical groups: a group of aware people and a group of anesthetized unaware people.
- PCC calculated every 1.25 seconds, is a rigorously defined mathematical probability, and as such, varies between zero and one.
- Observation mediation logic 25 mediates between the different observers and indices to produce a final set of output parameters, including the PSI.
- the initial PSI is the starting point for observer mediation logic and is simply a linear range expansion of the PCC by a factor of 100.
- the initial PSI 152 also referred to as the PSI, undergoes a piecewise-linear transformation 153 that re-scales it according to the following formula:
- Eye blink information is incorporated into the PSI 154 only prior to LOC, and only if the rPSI is greater than the LOC threshold of 50.
- An epoch is considered an eye blink epoch only if there are also no other types of artifact detected.
- the new PSI that includes the information represented by the pSR is referred to as the nPSI.
- the nPSI is constructed as a function of the rPSI and the pSR, denoted as nPSI(pSR,rPSI) 144 .
- nPSI(0, rPSI) 15 17 ⁇ rPSI + nPSI bot 21
- nPSI bot 25 - 15 2 17 ⁇ 11.7647 22
- nPSI ( pSR ⁇ 50 ,rPSI ) 0 24
- the PSI that incorporates possible changes due to the F 1 ⁇ 5 index is called the tPSI.
- the tPSI is a function of EMG and the nPSI.
- the tPSI is considered a good data point and is painted non-white, even though the underlying PSI may have been artifacted and would have otherwise been painted white.
- the PSI is considered modified by EMG only when the change is greater than 1.
- the third factor in the equation embodies the idea that as the nPSI gets larger, there is a smaller and smaller remaining range into which the tPSI can change. The change is limited to only part of this remaining range.
- the maximum of this limiting part is defined by the last term which also has the functional form of f(x).
- the maximum is itself a rising function of the FP 1 ⁇ 5 index with a midpoint at a large value of 10.25 and a relatively large transition width of 3.0. This means that for most typical values of the FP 1 ⁇ 5 index, the change is limited to a maximum value of about 80. This maximum will increase as the FP 1 ⁇ 5 index increases.
- the EMG B5 baseline is adaptively determined as follows: The EMG B5 index over the past three minutes is stored in two windows, or buffers. The first holds the indices for the oldest two minutes (of the three minutes) and the second holds the most recent 1 minute (of the three minutes). For each of these windows, the averages and standard deviations are calculated at every update (every 1.25 seconds).
- the adaptive baseline, L is set to the average in the first window, A 1 :
- the baseline in the beginning of the case is set to zero (the population baseline, since the EMG B5 z-scores used have been normalized to the population baseline).
- the EMG B5 term is continuously monitored for conditions that will allow the setting of a new baseline. This allows the adaptation of EMG B5 modifications to individual patient differences.
- the adaptive baseline algorithm is described later in the section.
- the conditions for declaring a Repeated PSI are distinct from the conditions for Repeated Probabilities.
- a Repeated Probability is generated if artifacts make an FFT unavailable.
- eye blink information can modify the oPSI′.
- the nPSI can be calculated from repeated probabilities. If the pSR happens to change during repeated probabilities, the nPSI will vary even if the underlying probability does not.
- EMG modifications can also be active during repeated probabilities.
- Artifacted PSI's are distinct from Repeated PSI's.
- the Artifacted PSI declaration is made on the 2.5-second PSI values. Repeated 1.25-second PSI's or repeated full-epoch PSI's are possible (through the rules in the previous sections).
- a 2.5-second PSI is declared an Artifacted PSI if the 2.5 second PSI is a repeated PSI AND the Artifact Index is greater than 30.
- the Trend PSI is the running average of four 2.5 second PSI's, whether it is an Artifacted PSI or not. In the beginning of the case, the initial value of the running average is the population value of 95 for awake patients.
- the Trend PSI is the one of the four output parameters of the PSI 4000 Algorithm.
- the raw measure buffer of raw measure sets does has less than 24 overlapped-epochs of raw measure sets stored. EEG data acquisition is being performed, artifact analysis is being done, and FFT calculations are being made on good data. Each calculated raw measure set is added to the raw measure buffer. The following are NOT calculated: raw components, Z components, the PCC, and the PSI, and the EMG Index. The SR and the Artifact Index are calculated during this period.
- the raw measure buffer has 24 or more (up to 32) overlapped-epochs of raw measure sets stored. EEG data acquisition is being performed, artifact analysis is being done, and FFT calculations are being made on good data. If the raw measure buffer has 32 raw measure sets, the oldest raw measure set is thrown away before the most recently calculated measure set is added. During this mode, all four output parameters are calculated from non-artifacted data. The most notable feature of this mode is the incorporation of eye blink information from artifact analysis into the PSI.
- the Algorithm determines that sufficient data has been accumulated after the raw measure buffer has accumulated 24 overlapped-epochs of raw measure sets calculated from FFT data.
- FFT data can only be calculated from non-artifacted epochs. Thus the time spent in this state is variable, depending on the amount of artifacts present in the data.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Surgery (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Artificial Intelligence (AREA)
- Signal Processing (AREA)
- Psychiatry (AREA)
- Physiology (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Anesthesiology (AREA)
- Evolutionary Computation (AREA)
- Fuzzy Systems (AREA)
- Mathematical Physics (AREA)
- Psychology (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
Abstract
A system which classifies patients according to their level of awareness or consciousness using measures derived solely from electroencephalograph (EEG) signals. The system comprises multiple observes of characteristics of signals, including artifact detectors, especially magnitude artifact detectors, eye blink detectors, stationarity/RMS detectors, slew rate detectors, and burst suppression detectors, and determination of power in certain frequency bands. The system produces a single derived probabilistic measure of conscious awareness called the patient state index (PSI) and displays values of trends in that index and values of an artifact index, an EMG index, and a suppression ratio in order to give the operator current information on the quality of the signal input. The PSI is derived from a statistical analysis using empirically derived population norms and other parameters.
Description
- This application is a continuation application of U.S. Ser. No. 09/431, 632, filed Nov. 2, 1999, now U.S. Pat. No. 6,317,627.
- The current invention relates to the field of medical anesthesia. More particularly it relates to the field of electronic monitoring of patients undergoing anesthesia, especially for use during and after surgical operations. The invention relates more specifically to the use of electroencephalograph (EEG) signals for electronically monitoring a patient's state of awareness.
- In current medical practice, at least for highly invasive surgery, a patient is placed under general anesthesia. Anesthesiology is a medical art practiced in the United States by and large by board certified physicians (anesthesiologists) and nurses (nurse anesthetists) specifically trained to administer anesthetic drugs and monitor patients under anesthesia. The state of patient anesthesia is attained by the controlled administration of various drugs with known anesthetic properties. These drugs cause the patient to lose consciousness, sensation, and motor control. The physician monitors the patient's state of awareness by means of a number of disparate clinical signs known empirically to provide useful and reliable information about the patient's state of unconsciousness.
- Generally, the patient is anesthetized prior to surgery by the specialized medical practitioner (anesthesiologist or nurse anesthetist), who administers one or more vapors or gases by inhalation or introduces anesthetic drugs intravenously. Volatile substances include nitrous oxide, sevoflurane, desflurane, flurane and isoflurane, and halothane. Intravenous anesthetics include pentothal, evipal, procaine, nitrous narcotic with propofol induction, methohexital, and etomidate.
- A correctly administered general anesthetic should remove any sensation of pain and any awareness of the operation itself. (Patients insufficiently deeply anesthetized have reported terror at becoming aware of the surgical procedure while paralyzed.)
- The anesthetic should further disable the patient's motor control so that the patient cannot move. Otherwise, the patient may exhibit involuntary (reflex) muscle movements, which can disturb the area being surgically manipulated. Prevention of movement can be accomplished by anesthetic agents acting on the central nervous system or with a blockade of the neuromuscular junction with muscle relaxants.
- Finally, the anesthesia must avoid depressing the patient's blood pressure so much as to reduce blood flow to the brain to a dangerous extent. Generally 50 mm Hg for mean arterial pressure is a lower limit.
- A trained anesthesiologist or nurse anesthetist will monitor the patient's vital signs such as respiration and pulse rates, check the patient's pupil dilation, and check certain reflexes, such as the lash reflex, and other physiological signs to estimate the depth of anesthesia. In some instances, however, either the practitioner does not have access to all of the required clinical information or other circumstances intervene. For example, in some procedures the patient is draped in such a way as to make observation of some clinical indicators difficult or impossible. In addition, in very lengthy procedures the attention of even the best practitioner can flag.
- In such circumstances it would frequently be useful to have an electronic monitor to track the patient's level of consciousness. In particular, it sometimes would be useful to have an instrument, which, once the plane of anesthesia is established qualitatively by the anesthesiologist using traditional clinical indicators, would indicate significant changes in the patient's state of anesthesia or patient responses to stimuli, which would indicate insufficient anesthesia.
- A number of inventors have developed systems for using EEG signals, generally in combination with other signals, to monitor anesthesia, sleep, or other states on the consciousness-unconsciousness continuum. Kaplan et al., U.S. Pat. No. 5,813,993, issued Sep. 29, 1998, disclosed a drowsiness detection system based on EEG signals. This invention relies heavily on frequencies in EEG signals above 30 Hz. It does not use any form of norming and in addition applies an ad hoc weighted sum of inverted spectral power coefficients. Maynard, U.S. Pat. No. 5,816,247, issued Oct. 6, 1998, uses a combination of time domain amplitude envelope analysis and frequency analysis in conjunction with a trainable neural network to classify awareness and sleep states. Kangas et al., U.S. Pat. No. 5,775,330, issued Jul. 7, 1998, uses transform processing and neural net analysis to classify states of anesthesia. The output of the neural net could be used to produce a single index of awareness. However, all of these prior art systems either represent an unnecessary level of complexity or an absence of empirical basis or both.
- A prior patent to John, U.S. Pat. No. 5,699,808, issued Dec. 23, 1997, discloses a system to monitor multiple patients simultaneously in the surgical recovery room or in intensive care. This system, however, combines certain features of EEG signals and other features including those of evoked potentials to arrive at an estimate of the patient's state of consciousness. It specifically incorporates the use of electrocardiograph (EKG) and electromyograph (EMG) electrodes and also input from a blood pressure detector and from a respiration monitor. This prior art system also requires evoked potentials, specifically Brainstem Auditory Evoked Response (BAER) and Brainstem Somatosensory Evoked Response (BSER). Use of evoked potentials, however, involves the use of additional disposables and a longer set-up time. Further, this system relies very heavily on self-norming and in particular on updating self-norming depending on the state of the patient.
- An earlier patent to the same inventor, John, U.S. Pat. No. 4,557,270, issued Dec. 10, 1985, suffered from additional and more severe limitations since it required measurement of blood temperatures and volumes. Finally, John, U.S. Pat. No. 4,545,388, issued Oct. 8, 1985, disclosed the basic process of self-norming of processed EEG data.
- Another inventor, Prichep, U.S. Pat. No. 5,083,571, issued Jan. 28, 1992, disclosed a significant advance in the utilization of EEG signals for diagnostic purposes. Prichep disclosed the use of discriminant analysis to sharpen the diagnostic capability of quantities derived from EEG signals with respect to certain well-known diagnostic categories of psychiatric illness. This work compared quantities derived from a patient with parameters derived from populations of persons thought to suffer from specific identified illnesses.
- Finally, a prior application which has not yet issued, John, U.S. patent application Ser. No. 09/217,010, filed Dec. 21, 1998, applied discriminant analysis to the statistical differentiation of unconscious from conscious states from EEG signals. However, this invention relied heavily on BAER and BSER signals and self-norming. In addition, this invention stated, with respect to Chamoun, U.S. Pat. No. 5,010,891, issued Apr. 30, 1991, that “the comparison of patients with a normal group, in itself, is not believed to provide reliable information in the surgical context of determining if a patient will be sufficiently anesthetized.” App. at p. 4. Since that time, however, the current inventors have learned from further investigation and experimentation that population-norming is sufficiently reliable and self-norming adds unnecessarily to the complexity of the system without adding to performance. What is therefore most lacking in all of these prior art inventions is simplicity and cost effectiveness.
- It is therefore an object of the current invention to provide an EEG based anesthesia monitoring system that completely avoids use of transducers for and inputs from other than EEG signals, that is, avoids the use of pulse, blood pressure, and respiration rate sensors and leads. It is a further object of this invention to provide an anesthesia monitoring system based on EEG signals, which completely avoids the need for BAER and BSER stimulation and response monitoring. It is a further object of this invention to provide an EEG based anesthesia monitoring system which dispenses with the cumbersome and error prone process of self-norming. It is another object of this invention to provide an EEG based anesthesia monitoring system which utilizes sample population-norming.
- The current invention comprises a system for using EEG signals to monitor the state of anesthesia of a patient at various stages preparatory to, during, and after administration of anesthetic and surgical operation, and in intensive care during recovery from the operation and anesthesia. The system comprises a headset attached to a patient, a patient module connected to the headset, apparatus for transmitting EEG signals to an analysis unit, and the analysis unit itself. The analysis unit further comprises a number of subsystems, but its essence is the Algorithm which processes the EEG signals into a parameter usable to estimate and/or track the patient's state of unconsciousness or consciousness while under anesthesia.
- The primary function of the analysis unit is to classify anesthetized patients according to their conscious state, as determined from an analysis of volunteer data using the OAA/S scale. The version of this scale used in this invention is:
Modified Observer's Assessment of Alertness/Sedation Scale Response Score Responds readily to name spoken in a normal tone 5 Lethargic response to name spoken in a normal tone 4 Responds only after name is called loudly and/or repeatedly 3 Responds only after mild shaking or prodding 2 Responds only to noxious stimulus and not to mild shaking or 1 prodding Does not respond to noxious stimulus 0 Burst Suppression −1 - The design of the analysis unit is based on the Multiple Observer Derived Measurement Model depicted in FIG. 1. An observer is a thread of execution and logic, an algorithm, which processes a stream of data and generates a measure of a characteristic(s) identified within the data stream. The principle is that is easier to construct individual observers tuned to specific characteristics in the data stream, than to create one observer that is tuned to classify an ensemble of characteristics in the data stream.
Observers 3 are classifier functions that detect signatures within the information. These signatures may be in the time domain, frequency domain, or a combination of the two domains. By tuning observers to specific signatures, selective filtering can be employed to improve the accuracy and latency of an observer. What may be noise to one observer may be critical information to another. This selective filtering increases the overall utilization of the acquired physiological information and thereby improving the performance of the final derived measure. - An
Observer Mediator 4 is responsible for logically combining these individual observations in to the single Derived Parameter. The Observer Mediator can weigh the individual observations by monitoring each observer's input signal quality and the context of the observation based on the patient state. The patient state is derived from the behavior of the derived parameter over time and this is fed back to the Observer Mediator. Functionally, either on demand or on a periodic basis, the Observer Mediator polls the Observers and based on patient state and the ‘quality’ of the individual observations, combines the observations into a single derived measure. The Derived Parameter may be enhanced in sensitivity or scope by either further tuning of established Observers or adding additional Observers. - The primary output of the PSA 4000 algorithm is a single derived parameter called the Patient State Index (PSI) that maps to the OAA/S scale independent of anesthetic agent. The implementation of the Multiple Observer Model for this measure of state of consciousness, the PSI, is shown in FIG. 2. In this system, electroencephalograph (EEG) signals are acquired from an array of electrodes on the patient's scalp. These raw EEG signals are filtered and decimated to reduce external noise and to satisfy data sampling rate (Nyquist) requirements.
- Following decimation, artifact analysis takes place. The EEG data is analyzed for validity and contamination. This step results in the setting of various artifact codes. After artifact analysis, the Eye-blink Observer and the Suppression Observer operate. This is followed by the calculation of the Artifact Index and the Suppression Ratio Index. For the FFT calculations, The Fast Fourier Transform (FFT) of the EEG data is calculated for each of the four channels. At this point, the system decomposes the Frequency Spectrum. In this operation the FFT spectral data is divided into frequency bands. After this, the EMG Index is calculated, and the EMG Beta-5 observer operates. The Discriminant Observer then makes its calculations, resulting in a Probability of Correct Classification based on parameters derived from sample populations. Finally, the Observer mediator combines the probability with other the output of the other three observers to the Patient State Index (PSI).
- The processing analyzes information in the 0.5 Hz to 50 Hz frequency range. As shown in FIG. 2, the sample data streams are divided into two primary streams: the FP1 channel is separately processed by the Beta5 Observer, all channels [FP1, FPz′, Pz, Cz] are processed by an ensemble of signal morphological classifiers13 (artifact detectors). By continuously monitoring the impedance of the
FP1 electrode 10 the Beta5 Observer's signal quality can be assessed. The FP1's signal quality is combined with Beta5 analysis 9 and evaluation 11 by the Beta5 Observer and propagated to the Observation Mediator. The outputs of the Signal Morphology Classifiers are four artifact free EEG data streams and a declaration of the types of artifacts detected. Two of the artifact classifiers propagate information to Observers. TheEyeblink Observer 19 is notified of the number and types of eyeblinks detected in the four EEG channels. TheSuppression Observer 20 is notified whether EEG suppression has been detected over the last time period. The artifact free EEG data is further processed by thePSI Discriminant Observer 18, which performs a more complex multiple component analysis that serves as the foundation of the consciousness algorithm. The four observations: Beta5, PSI Discriminant, Eyeblink and Suppression) are propagated to theObservation Mediator 25. The Mediator combines these observations with measures of signal quality and appropriateness of observations based on patient state into an update of the Patient State Index and the associated trend. The time course of the PSI is monitored and logic is applied to assess the patient's state and this information is fed back to the Observation Mediator. It is through the use of this Multiple Observer Model that a clinically functional measure of state of consciousness is realized. - The output of the Algorithm is a set of four processed parameters calculated every 2.5 seconds (each 2.5 second block is referred to as an epoch). These are the main output parameter, i.e., the Patient State Index (PSI); the Suppression Ratio (SR); the EMG index (EMG); and the Artifact Index (ART). The measures in addition to the PSI provide additional information to the instrument operator on either specific aspects of the patient state or data quality. These measures are shown in FIG. 2 to be directed to the User Interface. The Artifact Index is a measure of signal quality. The SR-Ratio is the percentage of time in the last minute the patient's EEG has been suppressed. The Beta2 component measure is related to the degree of muscle activity (EMG) detected. The outputs of this multiple observer based PSA 4000 algorithm is a periodic update of: the Patient State Index (the primary derived parameter), the Artifact Index, the Suppression Ratio and a measure of EMG activity.
- The
Patient State Index 164, the primary indicator of patient level of awareness, is developed to characterize the relative state of consciousness of an anesthetized patient. The Algorithm outputs a periodic update of this primary parameter. The Algorithm provides for upper and lower thresholds of this parameter within which the patient will be said to be in an appropriate level of unconsciousness for surgery. (Other levels may be appropriate for other conditions such as intensive care sedation.) The PSI range is defined to be from 0 to 100, with higher values indicating a higher level of consciousness or awareness. - The
Suppression Ratio 162 is an indicator of the relative amount of time that the patient's EEG waveforms exhibit a characteristic Burst Suppression pattern. The Burst Suppression pattern is accepted to be an indicator of deep levels of unconsciousness under sedation. In certain situations of traumatic head injury, for example, it is necessary to reduce the brain's need for oxygen by putting the patient into a drug induced (barbiturate) coma. This brain state is observed in the EEG as Burst Suppression. For most surgical procedures, burst suppression is considered an inappropriately deep level of sedation where the anesthesiologist would normally reduce drug flow rates accordingly. The Suppression Ratio is the percentage of epochs (2.5-second epochs) in the last one minute that have been declared as Suppressed Epochs. - The
EMG Index 163 is an indicator of muscle activity. Under certain conditions, an EMG response may be interpreted as an indicator of the patient's response to pain or stress. - The anesthesiologist's action would depend upon the conditions present when the EMG response occurs, as EMG is a normal indication at the end of surgery. During surgery, the anesthesiologist titrates additional hypnotic for stress or analgesic for pain accordingly. The EMG Index is a weighted percentage of half-epochs (over the past one minute) in which muscle activity, as measured by the power in the BETA-2 band, exceeds a threshold level. Newer epochs are weighted more heavily than the older ones.
- The
Artifact Index 165 is an indicator of data quality, or of the amount of artifacts present in the data. It is also a weighted percentage (over the past one minute). Increase in the artifact index is normal during any patient movement and may be associated with the use of certain equipment such as BOVI or train-of-four when applied to the face. Poor contact impedance aggravates all sources of artifact and will require intervention by the anesthesiologist to correct poor electrode contact with the patient. - FIG. 1 portrays the basic structure of the Multiple Observer Model.
- FIG. 2 is a more detailed illustration of the Multiple Observer Model.
- FIG. 3 shows the basic structure of the system
- FIG. 4 shows the basic logical flow of the Algorithm.
- FIG. 5 continues and supplements the logical flow diagram of the Algorithm.
- FIG. 6 shows the final stages of the logical flow of the Algorithm.
- FIG. 7 depicts the flow of information between buffers.
- In a related previous application, Ser. No. 09/113,946, filed Jul. 10, 1998, incorporated herein by reference as though fully set forth, one of the current inventors and others described a head set which can extract from the patient's head EEG signals from five favored locations of the set of international standard locations. The five favored locations are denoted in the international system by Fp1, Fp2, Fpz′, Cz, and Pz. In current embodiments these are electrically referenced to linked ear or linked mastoid contacts. EEG data from four of these five specific locations are analyzed. Alternatively, a more elaborate headset, such as that disclosed by Imran, U.S. Pat. No. 5,479,934, issued Jan. 2, 1996, can be used to obtain information from the four desired locations.
- As shown in FIG. 3, the PSA Patient Interface consists of a
Patient Module 42,patient interface cable 43, and aPatient Electrode Set 44 designed to provide a superior quality, programmable patient interface for EEG monitoring in the OR and ICU. The Patient Module is housed in a custom molded plastic enclosure with an integral universal-mounting bracket that facilitates attachment to an IV pole, bed sheet or rail. A detachable patient interface cable provides a quick connect/disconnect capability to the PSA appliance or Patient Module. EEG signals from the appliance are acquired with an isolated instrumentation grade, 4-channel pre-amplifier assembly and programmable multiplexed high speed A/D converter. The signal inputs are acquired referentially with reformatting provided by the Host application if necessary. Preamplifier optimization for EEG is standard, with EP and ECG optional by design. The combination of optically isolated data pathways, a low leakage/high isolation power converter and amplifiers with precise gain and band-pass matching results in greater than 120 dB CMRR. Calibration, Impedance Test, and Normal Operation are remotely controlled through the DSP Interface using commands generated by the Host Application. A full duplex connection is provided between the Patient Module and the DSP via dual optical-isolators that comply with VDE0884 for safety with extremely low leakage. The power converter is a UL Listed & Medical Grade. This extreme isolation results in negligible leakage currents and assures IEC601/UL2601 compliance with superior common mode performance. - The proprietary ISA bus DSP card provides a real time interactive link between the host and patient module and manages the acquisition, calibration and impedance functions of the patient module. Balanced differential drivers are used to minimize EMI associated with serial data transmission while providing the ability to extend the link to approximately 1000 feet. Filtering and decimation of the acquired data takes place in the DSP.
- The PSA 4000 analysis unit embodies and operates by means of a complex Algorithm referred to hereafter as the PSA 4000 Algorithm. The system operates in three distinct modes, sometimes referred to as states, with different characteristics. The three states are labeled as follows: 1) Data Accumulation; 2) Awake Patient; and 3) Unconscious Patient. Two very specific and well-defined events cause the transition of the system among these four states. These events are labeled as: 1) Sufficient Data Accumulated ; and 2) Loss of Consciousness. The identification of events and the switching among the states at the occurrence of an identified event is described further below following the description of the operation of the PSA 4000 Algorithm.
- The following notation is used in describing EEG data:
A sample is actually a set of four values, one for each of the Sample electrode, associated with a particular instant of time. j All samples have a sample index, denoted by j that increases with time. j = 0 The index of the most recent sample has index 0. All other samples therefore have a negative index. tj The time associated with a particular sample set is denoted by tj. The time resolution of the algorithm neglects the miniscule differences between time values of electrode values in a sample. Sj, S(j) The sample associated with a particular index j. S(tj) The sample associated with a particular time. - The basic operational modules of the PSA 4000 Algorithm are: EEG Data Collection, Filtering and Decimation; Artifact Detection and Signal Morphology Analysis; Eye-blink Observation; Suppression Observation; Calculation of Artifact Index; Calculation of Suppression Ratio Index; FFT Calculation; Spectral Band Decomposition; Calculation of the EMG Index; EMG Beta-5 Observation; Discriminant Observer Calculation of the Probability of Correct Classification; Observer Mediation for the PSI; and Display of the PSI, the Suppression Ratio Index, the EMG Index, and the Artifact Index.
- 1) EEG Data Collection, Filtering and Decimation
- The patient module (PM)42 acquires EEG data at a sampling rate of 2500 Hz. The sampling and processing are established to produce a frequency representation resolution of 0.25 Hz or better.
- Data on four channels from the headpiece are filtered and decimated by a 10-to-1 low
pass decimation filter 100, as shown in FIG. 5. This is done every 10 samples resulting in 1 sample every {fraction (1/250)} sec., for an effective sampling rate of fS=250 Hz. After the 10-1 decimation and filter, the EEG data passes through a high-pass filter 102 with a cut-off frequency of fh=0.4 Hz. The most recent L1 samples are used, where L1=fS/fh=625. Filtering starts at the sample s(−½L1) i.e., samples more recent than s(−½L1) are not filtered. The average of the most recent L1′−625 samples is subtracted from sample s(−½L1). We denote the filtered - sample by s′(−½L1):
- The filtered sample is stored in the buffer as shown in FIGS. 8 and 9 and refreshed every half epoch.
- 2) Artifact Detection and Signal Morphology Analysis
- Artifact detection and analysis are performed once every sample, i.e., 250 times per second in an Artifacter Bank103-108. This analysis results in an artifact type being associated with every sample that is classified as being affected by an artifact. Artifact types are also collated on an epoch-by-epoch basis. Artifact analysis is performed only onfiltered samples. As shown in FIG. 5, after the high-pass filter, the artifact engine analyzes data on four channels for 5 kinds of artifacts:
- a.
Magnitude 103 - b.
Slow Eye Blink 104 - c.
Fast Eye Blink 105 - d.
Slew rate 107 - e.
Stationarity 108. - These are later combined in an
Artifact Index module 106. - As is illustrated in FIG. 7, artifact analysis is done on a series of sample sets (sample buffers) of varying sizes. The magnitude, suppression, slew rate, and eye blink artifacts are checked on a buffer of 150 samples. These 150 samples (0.6 seconds) are older than the latest 312 of the 625 samples that have gone through the high-pass filter. Thus, they are identical with the newest 150 samples in the older half of the high-pass filter buffer. Similarly, the rms deviation artifact is checked on the 2000 samples (8.0 seconds) before (older than) the latest 75 of the 150 samples that were checked for the previous artifact types.
- The conditions used in checking for the various types of artifacts are:
- i) Magnitude
-
- classified as a magnitude artifact. Thus the condition is where Mthresh is the magnitude threshold. The magnitude threshold is different for different channels and is determined empirically.
- ii) Slew Rate
- The
slew rate detector 107 checks for sudden changes in the magnitude of samples. The rate of change cannot be greater than 15 μV over 20 ms. To check this, the detector obtains the largest sample and the smallest sample over the δslew samples older than s′(−½L1−½L2). If the difference between sample s′(−½L1−½L2) and either the largest or the smallest sample is greater than 15 μV, than a slew rate artifact is declared. Mathematically, the conditions can be expressed as: - where Lthresh is threshold for the slew rate artifact, equal to 15 μV. If either one of these conditions is satisfied, a slew rate artifact is declared.
- iii) Stationarity
-
- If this condition is satisfied for a given scale factor and limit term then a stationarity artifact is declared.
- 3) Eyeblink Observation
- The conditions for eye blinks,104 and 105, are checked only if the slew rate artifact is not detected because the slope required in a slew rate artifact is larger than the slope required for eye blinks The eye blink observer is mathematically similar to the slew rate detector, however, it checks for both positive and negative slopes together, i.e., it checks for EEG humps within certain parameters.
-
-
- conditions must be satisfied:
-
-
- If (
Equation 12 or Equation 13) AND (Equation 14 or Equation 15) is satisfied, then a large eyeblink is declared. The threshold parameters for eye blinks are determined empirically. - 4) Suppression Observation
-
-
- deviations) through
-
- associated with that sample. Thus the suppression condition is where Sthresh is the threshold for the Suppression Artifact. The thresholds are different for the different channels and are determined empirically.
- (a) Persistent Suppression Ratio (SR)
- The suppression Observer calculates a quantity called the persistent Suppression Ratio (pSR). It is defined as the percentage, over the past 2.5 minutes, of 2.5-second epochs in which a suppression artifact was detected. The pSR is used later in calculating the PSI from the PCC.
- The pSR is also calculated based on 2.5-sec suppressed epoch declarations, even though 1.25-sec suppressed epoch declarations are available from the current overlapping-FFT scheme. (Recall that the connecting rule is, if one of the two 1.25-sec epochs in a 2.5-sec epoch is declared suppressed, then the 2.5-sec epoch is declared suppressed.) The pSR is used later in calculating the PSI from the PCC.
- 5) Calculation of Artifact Index
- The 2.5-
second Artifact Index 106 is one of the four final output parameters communicated to the user of the PSA 4000. The Artifact Index is a time-weighted percentage of 48 overlapped epochs (1.25-second epochs) in the past one minute that were declared as artifacted epochs. The newer half-epochs are weighted more heavily than the older half-epochs. The Artifact Index is calculated every 1.25 seconds. - 6) Calculation of Suppression Ratio Index
- The Suppression Ratio (SR)143 is also one of the four final output parameters communicated to the user of the PSA 4000. The SR is defined as the percentage, over the past one minute, of 2.5-second epochs in which a suppression artifact was detected.
- 7) FFT Calculation
- Whenever 625 continuous good (non-artifacted) samples are calculated, the FFT of the time series (i.e., the set of 625 samples, also called an epoch) is calculated. A Hamming Window is applied to the time series data before the calculation of every FFT (see references). EEG data is sliced into 2.5-second periods, called epochs, containing 625 samples each. The Fourier Transform of an epoch of EEG data is calculated.
-
FFT calculations - 8) Spectral Band Decomposition
- The following band definitions are used in succeeding
Algorithmic calculations 146. The band definitions are given in units of Hertz (Hz).TABLE 1 Band Name Band definition (Hz) Δ 1.5-3.5 θ 3.5-7.5 α 7.5-12.5 β 12.5-25.0 β2 25.0-50.0 β5 35.0-50.0 tot 1.5-25.0 - The band tot spans only the bands Δ through β.
- 9) Calculation of the EMG Index
- The
EMG Index 148 is an indicator is a time-weighted percentage of 1.25-second epochs in the past one minute that had an F1β2 z-component of greater than 1.96. The newer half-epochs are weighted more heavily than the older half-epochs. - 10) EMG BETA-5 observation
- The F1β5
raw measure 126, is the power on the F1 channel in the β5 band. The F1β5 Z-component is the logarithm of the raw measure, and the F1β5 Z score is the population-normed Z-component. The F1β5 index is defined as a running average of the F1β5 Z-scores over the past twelve overlapped-epochs, in which the newest Z-score is limited to a maximum change of six population standard deviations from the latest running average. - 11) Discriminant observer calculations
- A
discriminant 149 is a function of statistical variable that maximizes the separation, in the variable space, of two groups of interest. It is usually a linear combination of the statistical variables. Thus, specification of the discriminant involves both specification of the variables and their weights. - i) Raw measures for the Discriminant Observers
- The Raw Measures used by the
discriminant observer 18 are defined by the following table:TABLE 1 Raw Measures as a combination of electrodes and bands tot Δ θ α β β2 FP1 P P FPz' F P P Cz P P Pz P P P - In this matrix, P refers to monopolar power and F refers to mean frequency. The raw measures are averaged over 32 overlapped-epochs.
- ii) Components for the Discriminant Observer
- The specific set of raw components calculated in the PSA 4000 Algorithm are as follows:
TABLE 2 Raw-components used in calculating the probability of correct classification Raw-Component # QUANTITY CHANNEL/BAND(S) 1 monop abs power FP1Tot 2 mean frequency FPz'Tot 3 monop abs power Pzα 4 power assymetry FP1Czβ2 5 monop power FPz'α 6 relative power PzΔ 7 monop power FPz'β 8 monop power Czβ 9 monop abs power FP1β2 - The first 8 are used in calculating the PCC. The 9th is used in calculating the final EMG Index output parameter. Z-components are obtained from the raw components by norming to a set of population means and standard deviations, which are obtained for each component from an experimental study of normative populations.
- iv) Z-Scores
- Z scores are either linear combinations of Z components, or identical to the z components. The z-score set used in the PSA 4000 discriminant is:
TABLE 3 Z-score set used in calculating the probability of correct classification Zscore # Definition in terms of Z- components 1 monop power (FP1Tot) 2 mean frequency (FPz'Tot) 3 monop power (FPz'α) - monop power (Pzα) 4 power assymetry (FP1Czβ2) 5 relative power (PzΔ) 6 monop power (FPz'β) - monop power (Czβ) - The z-scores are linearly combined with weights such that the linear combination will maximize the separation between the two statistical groups: a group of aware people and a group of anesthetized unaware people.
- v) Calculation of the Probability of Correct Classification
-
-
-
- The PCC, calculated every 1.25 seconds, is a rigorously defined mathematical probability, and as such, varies between zero and one.
- 12) Observer Mediation
-
Observation mediation logic 25 mediates between the different observers and indices to produce a final set of output parameters, including the PSI. - a) The Initial PSI
- The initial PSI is the starting point for observer mediation logic and is simply a linear range expansion of the PCC by a factor of 100.
- b) Variability Transformation of the initial PSI
- The
initial PSI 152, also referred to as the PSI, undergoes a piecewise-linear transformation 153 that re-scales it according to the following formula: - rPSI=1.7(oPSI)−70.0oPSI≧85.0
- rPSI=0.7(oPSI)+15.0 85.0>oPSI>15.0
- rPSI=1.7(oPSI)15.0>
oPSI 20 - The result is termed the rPSI.
- c) Mediation of Eye Blink Information
- Eye blink information is incorporated into the
PSI 154 only prior to LOC, and only if the rPSI is greater than the LOC threshold of 50. An epoch is considered an eye blink epoch only if there are also no other types of artifact detected. - If an eye blink epoch is detected during an Indeterminate Probability (i.e., before an rPSI can be calculated, because the raw measure buffer is not yet full) then an rPSI of 95 is reported. This rPSI and all succeeding rPSI values (until the buffer is full enough to calculate a value) are then treated as if they originated from a calculated probability, i.e., it undergoes the transformations and calculations that lead to the PSI. After this first eye blink, whenever an eye blink is detected, the current rPSI is averaged with 99, and the result becomes the current rPSI.
- d) Mediation of Suppression Information
- The new PSI that includes the information represented by the pSR is referred to as the nPSI. The nPSI is constructed as a function of the rPSI and the pSR, denoted as nPSI(pSR,rPSI)144.
-
-
- Another condition is the special case at pSR=15, i.e., nPSI(15, rPSI). We impose the condition
- nPSI(pSR=15, rPSI≧15)=15 23
- A third condition determining the transformation is case when pSR≧50. Then we have
- nPSI(pSR≧50,rPSI)=0 24
- e) Mediation of Beta5 Information
- Incorporation of EMG information into the PSI is based on the F1β5
index 140. This modification is a refinement of the EMG information already in the PSI by virtue of the F1β2 term. EMG modifications are possible only when the pSR=0, and only after a time threshold of 15 minutes after the declaration of Loss Of Consciousness (LOC). EMG modifications are not possible when the patient module is disconnected. In addition, there is a timeout period of ⅓ minute after the end of the PM Disconnect during which EMG modifications are not possible. When a BAD IMPEDANCE is detected, the EMG power used is the last one calculated before the BAD IMPEDANCE condition. - The PSI that incorporates possible changes due to the F1β5 index is called the tPSI. (The tPSI is a function of EMG and the nPSI.)
- When the PSI is modified by the F1β5 index then the tPSI is considered a good data point and is painted non-white, even though the underlying PSI may have been artifacted and would have otherwise been painted white. The PSI is considered modified by EMG only when the change is greater than 1.
- The change from nPSI to tPSI is calculated using the following equation: we express the change as the product of three functions:
- ΔPSI=f(F1,β5)g(nPSI)h(F1,β5, nPSI) 25
-
-
-
- In each of the three functions there is a functional form F(x)=(1+exp((x+c)/d))−1. This function creates a rising transition from 0 to 1, with the midpoint of the transition occurring at x=c, and the width (or sharpness) of the transition determined by d.
- Thus the first of the three equations above defines the contribution of the FP1β5 index as rising from zero around an index of approximately 1.25, and the second factor defines that the change can only occur be significant at nPSI values starting around a value of 19.
- The variable A in the equation above has a value of A=1.25−baseline. The baseline in the beginning of the case is set to zero (the population baseline, since the EMG B5 z-scores used have been normalized to the population baseline). However the EMG B5 term is continuously monitored for conditions that will allow the setting of a new baseline. This allows the adaptation of EMG B5 modifications to individual patient differences. The adaptive baseline algorithm is described later in this section.
- The third factor in the equation embodies the idea that as the nPSI gets larger, there is a smaller and smaller remaining range into which the tPSI can change. The change is limited to only part of this remaining range. The maximum of this limiting part is defined by the last term which also has the functional form of f(x). The maximum is itself a rising function of the FP1β5 index with a midpoint at a large value of 10.25 and a relatively large transition width of 3.0. This means that for most typical values of the FP1β5 index, the change is limited to a maximum value of about 80. This maximum will increase as the FP1β5 index increases.
- The tPSI is given by
- tPSI=
nPSI+ΔPSI 29 - The EMG B5 baseline is adaptively determined as follows: The EMG B5 index over the past three minutes is stored in two windows, or buffers. The first holds the indices for the oldest two minutes (of the three minutes) and the second holds the most recent 1 minute (of the three minutes). For each of these windows, the averages and standard deviations are calculated at every update (every 1.25 seconds).
- Every update, the following conditions on the averages and standard deviations are checked:
- (F1β5)1<A1 30
- |(F 1β5)1−(F 1β5)2 |<D 31
- σ2<S2 33
- σ1<S1 32
- If all four conditions are satisfied, then the adaptive baseline, L, is set to the average in the first window, A1:
- L=A1 34
- The variable A in the equation above has a value of A=1.25−baseline. The baseline in the beginning of the case is set to zero (the population baseline, since the EMG B5 z-scores used have been normalized to the population baseline). However the EMG B5 term is continuously monitored for conditions that will allow the setting of a new baseline. This allows the adaptation of EMG B5 modifications to individual patient differences. The adaptive baseline algorithm is described later in the section.
- f) Mediation of Artifact Information
- i) Repeated PSI
- The conditions for declaring a Repeated PSI are distinct from the conditions for Repeated Probabilities. A Repeated Probability is generated if artifacts make an FFT unavailable. However, several things can cause the PSI to vary even if the underlying probability is a repeated probability. First, eye blink information can modify the oPSI′. Secondly, the nPSI can be calculated from repeated probabilities. If the pSR happens to change during repeated probabilities, the nPSI will vary even if the underlying probability does not. Third, EMG modifications can also be active during repeated probabilities.
- The following conditions are used in the declaration of a Repeated PSI: if an epoch is an artifacted epoch, AND the PSI has NOT been modified by either eye blinks or EMG, AND the Artifact Index is greater than 30, then the tPSI is a Repeated PSI.
- “Repeated PSI” is merely terminology, carried over from “Repeated Probability”. It does not imply that the PSI is actually repeated, though in most cases it will be.
- ii) Artifacted PSI
- Artifacted PSI's are distinct from Repeated PSI's. The Artifacted PSI declaration is made on the 2.5-second PSI values. Repeated 1.25-second PSI's or repeated full-epoch PSI's are possible (through the rules in the previous sections). A 2.5-second PSI is declared an Artifacted PSI if the 2.5 second PSI is a repeated PSI AND the Artifact Index is greater than 30.
- iii) Trend PSI
- The Trend PSI is the running average of four 2.5 second PSI's, whether it is an Artifacted PSI or not. In the beginning of the case, the initial value of the running average is the population value of 95 for awake patients. The Trend PSI is the one of the four output parameters of the PSI 4000 Algorithm.
- As previously noted, the system operates in four distinct modes, each operating significantly differently. The four specifically defined states are as follows.
- 1) States
- a) Data Accumulation
- During Data Accumulation, the raw measure buffer of raw measure sets does has less than 24 overlapped-epochs of raw measure sets stored. EEG data acquisition is being performed, artifact analysis is being done, and FFT calculations are being made on good data. Each calculated raw measure set is added to the raw measure buffer. The following are NOT calculated: raw components, Z components, the PCC, and the PSI, and the EMG Index. The SR and the Artifact Index are calculated during this period.
- b) Awake State
- In Awake State, the raw measure buffer has 24 or more (up to 32) overlapped-epochs of raw measure sets stored. EEG data acquisition is being performed, artifact analysis is being done, and FFT calculations are being made on good data. If the raw measure buffer has 32 raw measure sets, the oldest raw measure set is thrown away before the most recently calculated measure set is added. During this mode, all four output parameters are calculated from non-artifacted data. The most notable feature of this mode is the incorporation of eye blink information from artifact analysis into the PSI.
- c) Unconscious State
- In Unconscious State, eye blink information is ignored and is NOT incorporated into the PSI. Otherwise, the operation of the Algorithm is the same as in Awake State.
- 1) Transition Events
- The following three transition events initiate a transition between the four states.
- a) Sufficient Data Accumulated
- The Algorithm determines that sufficient data has been accumulated after the raw measure buffer has accumulated 24 overlapped-epochs of raw measure sets calculated from FFT data. FFT data can only be calculated from non-artifacted epochs. Thus the time spent in this state is variable, depending on the amount of artifacts present in the data.
- b) Loss Of Consciousness
- If the PSI has 18 consecutive non-repeated values below 50, Loss Of Consciousness is declared. This declaration is used to disable the incorporation of eye blink information into the PSI.
Claims (3)
1. An apparatus for classifying the level of awareness of a patient using electroencephalograph (EEG) signals, comprising:
a. a plurality of patient electrodes whereby a plurality of patient EEG signals is acquired;
b. a patient module connected to the patient electrode set, said patient module having a plurality of channels corresponding to the plurality of patient electrodes; and
c. at least one analysis unit connected to the patient module, said analysis unit having a plurality of channels corresponding to the plurality of patient electrodes, and said analysis unit comprising,
i. a plurality of modules comprising observers configured to produce measures of specific characteristics in the plural EEG signals;
ii. an observer mediator which mediates among plural outputs of the plural observers according to a mediation logic, whereby the at least one observer mediator produces at least one output parameter characterizing the patient's state of anesthesia; and
wherein one of the modules comprising an observer comprises a subsystem which constructs and sends to the observer mediator a statistical discriminant based on plural statistical variables derived from power and frequency information extracted from plural EEG signals.
2. The apparatus of claim 1 , wherein the plural observers in each of the plural channels are plural classifiers which detect signatures within each of the plural EEG signals.
3. The apparatus of claim 1 in which the single derived parameter is a Patient State Index.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/007,849 US20020082513A1 (en) | 1999-11-02 | 2001-11-13 | Anesthesia monitoring system based on electroencephalographic signals |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/431,632 US6317627B1 (en) | 1999-11-02 | 1999-11-02 | Anesthesia monitoring system based on electroencephalographic signals |
US10/007,849 US20020082513A1 (en) | 1999-11-02 | 2001-11-13 | Anesthesia monitoring system based on electroencephalographic signals |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/431,632 Continuation US6317627B1 (en) | 1999-11-02 | 1999-11-02 | Anesthesia monitoring system based on electroencephalographic signals |
Publications (1)
Publication Number | Publication Date |
---|---|
US20020082513A1 true US20020082513A1 (en) | 2002-06-27 |
Family
ID=23712775
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/431,632 Expired - Lifetime US6317627B1 (en) | 1999-11-02 | 1999-11-02 | Anesthesia monitoring system based on electroencephalographic signals |
US10/007,849 Abandoned US20020082513A1 (en) | 1999-11-02 | 2001-11-13 | Anesthesia monitoring system based on electroencephalographic signals |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/431,632 Expired - Lifetime US6317627B1 (en) | 1999-11-02 | 1999-11-02 | Anesthesia monitoring system based on electroencephalographic signals |
Country Status (1)
Country | Link |
---|---|
US (2) | US6317627B1 (en) |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040225179A1 (en) * | 2003-02-28 | 2004-11-11 | Consolidated Research Of Richmond, Inc. | Automated insomnia treatment system |
US20040236240A1 (en) * | 2000-12-07 | 2004-11-25 | Kraus Baruch Shlomo | Automated interpretive medical care system and methodology |
US20040243017A1 (en) * | 2003-05-06 | 2004-12-02 | Elvir Causevic | Anesthesia and sedation monitoring system and method |
US20060019224A1 (en) * | 2004-07-23 | 2006-01-26 | Pics, Inc. | Insomnia assessment and treatment device and method |
US20070016095A1 (en) * | 2005-05-10 | 2007-01-18 | Low Philip S | Automated detection of sleep and waking states |
US20070071160A1 (en) * | 2005-09-27 | 2007-03-29 | Akihiko Nishide | X-ray ct apparatus |
WO2007059248A2 (en) * | 2005-11-15 | 2007-05-24 | Hospira, Inc | System for monitoring and separating eeg and emg signals |
US20070167694A1 (en) * | 2005-12-21 | 2007-07-19 | Everest Biomedical Instruments Co. | Integrated Portable Anesthesia and Sedation Monitoring Apparatus |
US20070185697A1 (en) * | 2006-02-07 | 2007-08-09 | Microsoft Corporation | Using electroencephalograph signals for task classification and activity recognition |
US20080317672A1 (en) * | 2007-06-20 | 2008-12-25 | The General Electric Company | Detection of anomalies in measurement of level of hypnosis |
US20100094103A1 (en) * | 2003-02-28 | 2010-04-15 | Consolidated Research Of Richmond, Inc | Automated treatment system for sleep |
DE102009053256A1 (en) * | 2009-11-06 | 2011-05-19 | Baars, Jan H., Dr. med. | Method for determining the analgesic level of a sedated or anaesthetized individual |
US20110224569A1 (en) * | 2010-03-10 | 2011-09-15 | Robert Isenhart | Method and device for removing eeg artifacts |
US20110295196A1 (en) * | 2009-01-15 | 2011-12-01 | Hopital Foch | System for controlling means for injection of anesthetics or sedatives |
CN103040459A (en) * | 2013-01-05 | 2013-04-17 | 西安交通大学 | Method of high-fidelity filtering for power frequency interferences in multichannel feeble physiological information recording system |
CN103169466A (en) * | 2013-04-01 | 2013-06-26 | 张宇奇 | Algesia monitoring system and monitoring method for anesthesia |
US8666484B2 (en) | 2011-11-25 | 2014-03-04 | Persyst Development Corporation | Method and system for displaying EEG data |
US20140081094A1 (en) * | 2011-05-02 | 2014-03-20 | Denis Jordan | Method for consciousness and pain monitoring, module for analyzing eeg signals, and eeg anesthesia monitor |
US8821397B2 (en) | 2010-09-28 | 2014-09-02 | Masimo Corporation | Depth of consciousness monitor including oximeter |
US8838198B2 (en) | 2008-11-14 | 2014-09-16 | Neuronetrix Solutions, Llc | Electrode system |
US9364163B2 (en) | 2012-01-24 | 2016-06-14 | Neurovigil, Inc. | Correlating brain signal to intentional and unintentional changes in brain state |
US9775545B2 (en) | 2010-09-28 | 2017-10-03 | Masimo Corporation | Magnetic electrical connector for patient monitors |
US9849241B2 (en) | 2013-04-24 | 2017-12-26 | Fresenius Kabi Deutschland Gmbh | Method of operating a control device for controlling an infusion device |
US10154815B2 (en) | 2014-10-07 | 2018-12-18 | Masimo Corporation | Modular physiological sensors |
US10537677B2 (en) | 2009-01-15 | 2020-01-21 | Medsteer | System for controlling injectors of anaesthetics or sedatives with a view to inducing anaesthesia or sedation |
US11273283B2 (en) | 2017-12-31 | 2022-03-15 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to enhance emotional response |
US11364361B2 (en) | 2018-04-20 | 2022-06-21 | Neuroenhancement Lab, LLC | System and method for inducing sleep by transplanting mental states |
US11452839B2 (en) | 2018-09-14 | 2022-09-27 | Neuroenhancement Lab, LLC | System and method of improving sleep |
US11717686B2 (en) | 2017-12-04 | 2023-08-08 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to facilitate learning and performance |
US11723579B2 (en) | 2017-09-19 | 2023-08-15 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement |
US11786694B2 (en) | 2019-05-24 | 2023-10-17 | NeuroLight, Inc. | Device, method, and app for facilitating sleep |
Families Citing this family (331)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX9702434A (en) | 1991-03-07 | 1998-05-31 | Masimo Corp | Signal processing apparatus. |
US5638818A (en) | 1991-03-21 | 1997-06-17 | Masimo Corporation | Low noise optical probe |
US8019400B2 (en) | 1994-10-07 | 2011-09-13 | Masimo Corporation | Signal processing apparatus |
EP1905352B1 (en) | 1994-10-07 | 2014-07-16 | Masimo Corporation | Signal processing method |
US6002952A (en) | 1997-04-14 | 1999-12-14 | Masimo Corporation | Signal processing apparatus and method |
US6229856B1 (en) | 1997-04-14 | 2001-05-08 | Masimo Corporation | Method and apparatus for demodulating signals in a pulse oximetry system |
EP1082050B1 (en) | 1998-06-03 | 2011-08-24 | Masimo Corporation | Stereo pulse oximeter |
US7245953B1 (en) | 1999-04-12 | 2007-07-17 | Masimo Corporation | Reusable pulse oximeter probe and disposable bandage apparatii |
US6721585B1 (en) | 1998-10-15 | 2004-04-13 | Sensidyne, Inc. | Universal modular pulse oximeter probe for use with reusable and disposable patient attachment devices |
US6463311B1 (en) | 1998-12-30 | 2002-10-08 | Masimo Corporation | Plethysmograph pulse recognition processor |
US6684090B2 (en) | 1999-01-07 | 2004-01-27 | Masimo Corporation | Pulse oximetry data confidence indicator |
US6360114B1 (en) | 1999-03-25 | 2002-03-19 | Masimo Corporation | Pulse oximeter probe-off detector |
US6515273B2 (en) | 1999-08-26 | 2003-02-04 | Masimo Corporation | System for indicating the expiration of the useful operating life of a pulse oximetry sensor |
ES2263499T3 (en) * | 1999-10-27 | 2006-12-16 | Hospira Sedation, Inc. | MODULE TO PURCHASE ELECTROENCEPHALOGRAPHIC SIGNS FROM A PATIENT. |
US6377829B1 (en) | 1999-12-09 | 2002-04-23 | Masimo Corporation | Resposable pulse oximetry sensor |
DE10015026C2 (en) * | 2000-03-25 | 2002-05-08 | Draeger Medical Ag | Arrangement and method for regulating a numerical value for patient ventilation |
US6757558B2 (en) * | 2000-07-06 | 2004-06-29 | Algodyne, Ltd. | Objective pain measurement system and method |
EP1309270B1 (en) | 2000-08-18 | 2009-07-01 | Masimo Corporation | Dual-mode pulse oximeter |
RU2330607C2 (en) * | 2001-06-13 | 2008-08-10 | Компьюмедикс Лимитед | Methods and device for consciousness monitoring |
US6850787B2 (en) | 2001-06-29 | 2005-02-01 | Masimo Laboratories, Inc. | Signal component processor |
US6697658B2 (en) | 2001-07-02 | 2004-02-24 | Masimo Corporation | Low power pulse oximeter |
US7355512B1 (en) | 2002-01-24 | 2008-04-08 | Masimo Corporation | Parallel alarm processor |
US6850788B2 (en) | 2002-03-25 | 2005-02-01 | Masimo Corporation | Physiological measurement communications adapter |
US7373198B2 (en) * | 2002-07-12 | 2008-05-13 | Bionova Technologies Inc. | Method and apparatus for the estimation of anesthetic depth using wavelet analysis of the electroencephalogram |
CN100518846C (en) * | 2002-10-03 | 2009-07-29 | 斯科特实验室公司 | Neural networks in sedation and analgesia systems |
US7189204B2 (en) | 2002-12-04 | 2007-03-13 | Cardiac Pacemakers, Inc. | Sleep detection using an adjustable threshold |
US6970792B1 (en) | 2002-12-04 | 2005-11-29 | Masimo Laboratories, Inc. | Systems and methods for determining blood oxygen saturation values using complex number encoding |
US7919713B2 (en) | 2007-04-16 | 2011-04-05 | Masimo Corporation | Low noise oximetry cable including conductive cords |
US7764982B2 (en) | 2005-03-01 | 2010-07-27 | Masimo Laboratories, Inc. | Multiple wavelength sensor emitters |
US6920345B2 (en) | 2003-01-24 | 2005-07-19 | Masimo Corporation | Optical sensor including disposable and reusable elements |
US7003338B2 (en) | 2003-07-08 | 2006-02-21 | Masimo Corporation | Method and apparatus for reducing coupling between signals |
US7500950B2 (en) | 2003-07-25 | 2009-03-10 | Masimo Corporation | Multipurpose sensor port |
US7887493B2 (en) | 2003-09-18 | 2011-02-15 | Cardiac Pacemakers, Inc. | Implantable device employing movement sensing for detecting sleep-related disorders |
US8002553B2 (en) | 2003-08-18 | 2011-08-23 | Cardiac Pacemakers, Inc. | Sleep quality data collection and evaluation |
ATE413902T1 (en) | 2003-08-18 | 2008-11-15 | Cardiac Pacemakers Inc | PATIENT MONITORING SYSTEM |
US8606356B2 (en) | 2003-09-18 | 2013-12-10 | Cardiac Pacemakers, Inc. | Autonomic arousal detection system and method |
US7668591B2 (en) | 2003-09-18 | 2010-02-23 | Cardiac Pacemakers, Inc. | Automatic activation of medical processes |
US7483729B2 (en) | 2003-11-05 | 2009-01-27 | Masimo Corporation | Pulse oximeter access apparatus and method |
WO2005050525A1 (en) * | 2003-11-12 | 2005-06-02 | Draeger Medical Systems, Inc. | A healthcare processing device and display system |
US7438683B2 (en) | 2004-03-04 | 2008-10-21 | Masimo Corporation | Application identification sensor |
US7415297B2 (en) | 2004-03-08 | 2008-08-19 | Masimo Corporation | Physiological parameter system |
CA2464029A1 (en) | 2004-04-08 | 2005-10-08 | Valery Telfort | Non-invasive ventilation monitor |
US7447541B2 (en) * | 2004-06-30 | 2008-11-04 | Instrumentarium Corporation | Monitoring subcortical responsiveness of a patient |
US7343186B2 (en) | 2004-07-07 | 2008-03-11 | Masimo Laboratories, Inc. | Multi-wavelength physiological monitor |
US9341565B2 (en) | 2004-07-07 | 2016-05-17 | Masimo Corporation | Multiple-wavelength physiological monitor |
US7937128B2 (en) | 2004-07-09 | 2011-05-03 | Masimo Corporation | Cyanotic infant sensor |
US7254429B2 (en) | 2004-08-11 | 2007-08-07 | Glucolight Corporation | Method and apparatus for monitoring glucose levels in a biological tissue |
US8036727B2 (en) | 2004-08-11 | 2011-10-11 | Glt Acquisition Corp. | Methods for noninvasively measuring analyte levels in a subject |
US20060058700A1 (en) * | 2004-08-26 | 2006-03-16 | Marro Dominic P | Patient sedation monitor |
WO2006110859A2 (en) | 2005-04-13 | 2006-10-19 | Glucolight Corporation | Method for data reduction and calibration of an oct-based blood glucose monitor |
US7805187B2 (en) * | 2005-07-07 | 2010-09-28 | The General Electric Company | Monitoring of the cerebral state of a subject |
US12014328B2 (en) | 2005-07-13 | 2024-06-18 | Vccb Holdings, Inc. | Medicine bottle cap with electronic embedded curved display |
KR100719068B1 (en) * | 2005-09-14 | 2007-05-17 | 재단법인 한국정신과학연구소 | Health diagnosis device and its method using pattern analysis of cumulative data through fast Fourier transform of EEG data measured in frontal lobe |
US7962188B2 (en) | 2005-10-14 | 2011-06-14 | Masimo Corporation | Robust alarm system |
US8233955B2 (en) | 2005-11-29 | 2012-07-31 | Cercacor Laboratories, Inc. | Optical sensor including disposable and reusable elements |
US8182443B1 (en) | 2006-01-17 | 2012-05-22 | Masimo Corporation | Drug administration controller |
US8219172B2 (en) | 2006-03-17 | 2012-07-10 | Glt Acquisition Corp. | System and method for creating a stable optical interface |
US9176141B2 (en) | 2006-05-15 | 2015-11-03 | Cercacor Laboratories, Inc. | Physiological monitor calibration system |
US7941199B2 (en) | 2006-05-15 | 2011-05-10 | Masimo Laboratories, Inc. | Sepsis monitor |
US8998809B2 (en) | 2006-05-15 | 2015-04-07 | Cercacor Laboratories, Inc. | Systems and methods for calibrating minimally invasive and non-invasive physiological sensor devices |
WO2007140478A2 (en) | 2006-05-31 | 2007-12-06 | Masimo Corporation | Respiratory monitoring |
US10188348B2 (en) | 2006-06-05 | 2019-01-29 | Masimo Corporation | Parameter upgrade system |
FR2903314B1 (en) * | 2006-07-10 | 2018-01-12 | Universite Pierre Et Marie Curie | DEVICE FOR DETECTING INAPPROPRIATE ADJUSTMENT OF A VENTILATORY ASSISTANCE MACHINE USED ON A MAMMAL. |
US8457707B2 (en) | 2006-09-20 | 2013-06-04 | Masimo Corporation | Congenital heart disease monitor |
US8840549B2 (en) | 2006-09-22 | 2014-09-23 | Masimo Corporation | Modular patient monitor |
US9161696B2 (en) | 2006-09-22 | 2015-10-20 | Masimo Corporation | Modular patient monitor |
ES2531254T3 (en) | 2006-09-29 | 2015-03-12 | Univ California | Outbreak suppression monitor for induced coma |
US7880626B2 (en) | 2006-10-12 | 2011-02-01 | Masimo Corporation | System and method for monitoring the life of a physiological sensor |
US8255026B1 (en) | 2006-10-12 | 2012-08-28 | Masimo Corporation, Inc. | Patient monitor capable of monitoring the quality of attached probes and accessories |
US9192329B2 (en) | 2006-10-12 | 2015-11-24 | Masimo Corporation | Variable mode pulse indicator |
US8265723B1 (en) | 2006-10-12 | 2012-09-11 | Cercacor Laboratories, Inc. | Oximeter probe off indicator defining probe off space |
US8280473B2 (en) | 2006-10-12 | 2012-10-02 | Masino Corporation, Inc. | Perfusion index smoother |
US9861305B1 (en) | 2006-10-12 | 2018-01-09 | Masimo Corporation | Method and apparatus for calibration to reduce coupling between signals in a measurement system |
US8600467B2 (en) | 2006-11-29 | 2013-12-03 | Cercacor Laboratories, Inc. | Optical sensor including disposable and reusable elements |
EP2096994B1 (en) | 2006-12-09 | 2018-10-03 | Masimo Corporation | Plethysmograph variability determination |
US8852094B2 (en) | 2006-12-22 | 2014-10-07 | Masimo Corporation | Physiological parameter system |
US8652060B2 (en) | 2007-01-20 | 2014-02-18 | Masimo Corporation | Perfusion trend indicator |
US9402558B2 (en) * | 2007-04-05 | 2016-08-02 | New York University | System and method for pain detection and computation of a pain quantification index |
US8374665B2 (en) | 2007-04-21 | 2013-02-12 | Cercacor Laboratories, Inc. | Tissue profile wellness monitor |
US8764671B2 (en) | 2007-06-28 | 2014-07-01 | Masimo Corporation | Disposable active pulse sensor |
US8048040B2 (en) | 2007-09-13 | 2011-11-01 | Masimo Corporation | Fluid titration system |
US8310336B2 (en) | 2008-10-10 | 2012-11-13 | Masimo Corporation | Systems and methods for storing, analyzing, retrieving and displaying streaming medical data |
JP5296793B2 (en) | 2007-10-12 | 2013-09-25 | マシモ コーポレイション | Connector assembly |
WO2009059248A1 (en) * | 2007-10-31 | 2009-05-07 | Emsense Corporation | Systems and methods providing distributed collection and centralized processing of physiological responses from viewers |
WO2009079366A2 (en) * | 2007-12-18 | 2009-06-25 | New York University | System and method for assessing efficacy of therapeutic agents |
US8571617B2 (en) | 2008-03-04 | 2013-10-29 | Glt Acquisition Corp. | Flowometry in optical coherence tomography for analyte level estimation |
WO2009134724A1 (en) | 2008-05-02 | 2009-11-05 | Masimo Corporation | Monitor configuration system |
JP2011519684A (en) | 2008-05-05 | 2011-07-14 | マシモ コーポレイション | Pulse oximeter system with electrical disconnect circuit |
US20100004518A1 (en) | 2008-07-03 | 2010-01-07 | Masimo Laboratories, Inc. | Heat sink for noninvasive medical sensor |
US8203438B2 (en) | 2008-07-29 | 2012-06-19 | Masimo Corporation | Alarm suspend system |
US8630691B2 (en) | 2008-08-04 | 2014-01-14 | Cercacor Laboratories, Inc. | Multi-stream sensor front ends for noninvasive measurement of blood constituents |
SE532941C2 (en) | 2008-09-15 | 2010-05-18 | Phasein Ab | Gas sampling line for breathing gases |
US8401602B2 (en) | 2008-10-13 | 2013-03-19 | Masimo Corporation | Secondary-emitter sensor position indicator |
US8346330B2 (en) | 2008-10-13 | 2013-01-01 | Masimo Corporation | Reflection-detector sensor position indicator |
US8771204B2 (en) | 2008-12-30 | 2014-07-08 | Masimo Corporation | Acoustic sensor assembly |
US8588880B2 (en) | 2009-02-16 | 2013-11-19 | Masimo Corporation | Ear sensor |
US10007758B2 (en) | 2009-03-04 | 2018-06-26 | Masimo Corporation | Medical monitoring system |
US10032002B2 (en) | 2009-03-04 | 2018-07-24 | Masimo Corporation | Medical monitoring system |
US9218454B2 (en) | 2009-03-04 | 2015-12-22 | Masimo Corporation | Medical monitoring system |
US9323894B2 (en) | 2011-08-19 | 2016-04-26 | Masimo Corporation | Health care sanitation monitoring system |
US8388353B2 (en) | 2009-03-11 | 2013-03-05 | Cercacor Laboratories, Inc. | Magnetic connector |
US8155736B2 (en) * | 2009-03-16 | 2012-04-10 | Neurosky, Inc. | EEG control of devices using sensory evoked potentials |
US8391966B2 (en) * | 2009-03-16 | 2013-03-05 | Neurosky, Inc. | Sensory-evoked potential (SEP) classification/detection in the time domain |
US20100256515A1 (en) * | 2009-04-03 | 2010-10-07 | Egeth Marc J | Communication with and consciousness-assessment of anesthetized surgery patients |
US8914102B1 (en) | 2009-04-20 | 2014-12-16 | University Of South Florida | Method and device for anesthesiology measurement and control |
WO2010135373A1 (en) | 2009-05-19 | 2010-11-25 | Masimo Corporation | Disposable components for reusable physiological sensor |
US8571619B2 (en) | 2009-05-20 | 2013-10-29 | Masimo Corporation | Hemoglobin display and patient treatment |
US20110208015A1 (en) | 2009-07-20 | 2011-08-25 | Masimo Corporation | Wireless patient monitoring system |
US8471713B2 (en) | 2009-07-24 | 2013-06-25 | Cercacor Laboratories, Inc. | Interference detector for patient monitor |
US8473020B2 (en) | 2009-07-29 | 2013-06-25 | Cercacor Laboratories, Inc. | Non-invasive physiological sensor cover |
US8688183B2 (en) | 2009-09-03 | 2014-04-01 | Ceracor Laboratories, Inc. | Emitter driver for noninvasive patient monitor |
US20110172498A1 (en) | 2009-09-14 | 2011-07-14 | Olsen Gregory A | Spot check monitor credit system |
US9579039B2 (en) | 2011-01-10 | 2017-02-28 | Masimo Corporation | Non-invasive intravascular volume index monitor |
US20110137297A1 (en) | 2009-09-17 | 2011-06-09 | Kiani Massi Joe E | Pharmacological management system |
US8571618B1 (en) | 2009-09-28 | 2013-10-29 | Cercacor Laboratories, Inc. | Adaptive calibration system for spectrophotometric measurements |
US20110082711A1 (en) | 2009-10-06 | 2011-04-07 | Masimo Laboratories, Inc. | Personal digital assistant or organizer for monitoring glucose levels |
US8755535B2 (en) | 2009-10-15 | 2014-06-17 | Masimo Corporation | Acoustic respiratory monitoring sensor having multiple sensing elements |
US10463340B2 (en) | 2009-10-15 | 2019-11-05 | Masimo Corporation | Acoustic respiratory monitoring systems and methods |
US8870792B2 (en) | 2009-10-15 | 2014-10-28 | Masimo Corporation | Physiological acoustic monitoring system |
US8430817B1 (en) | 2009-10-15 | 2013-04-30 | Masimo Corporation | System for determining confidence in respiratory rate measurements |
US8523781B2 (en) | 2009-10-15 | 2013-09-03 | Masimo Corporation | Bidirectional physiological information display |
WO2011047216A2 (en) | 2009-10-15 | 2011-04-21 | Masimo Corporation | Physiological acoustic monitoring system |
US9848800B1 (en) | 2009-10-16 | 2017-12-26 | Masimo Corporation | Respiratory pause detector |
US9839381B1 (en) | 2009-11-24 | 2017-12-12 | Cercacor Laboratories, Inc. | Physiological measurement system with automatic wavelength adjustment |
DE112010004682T5 (en) | 2009-12-04 | 2013-03-28 | Masimo Corporation | Calibration for multi-level physiological monitors |
US9153112B1 (en) | 2009-12-21 | 2015-10-06 | Masimo Corporation | Modular patient monitor |
WO2011091059A1 (en) | 2010-01-19 | 2011-07-28 | Masimo Corporation | Wellness analysis system |
GB2490832B (en) | 2010-03-01 | 2016-09-21 | Masimo Corp | Adaptive alarm system |
EP2544591B1 (en) | 2010-03-08 | 2021-07-21 | Masimo Corporation | Reprocessing of a physiological sensor |
US8700141B2 (en) * | 2010-03-10 | 2014-04-15 | Brainscope Company, Inc. | Method and apparatus for automatic evoked potentials assessment |
US9307928B1 (en) | 2010-03-30 | 2016-04-12 | Masimo Corporation | Plethysmographic respiration processor |
US8712494B1 (en) | 2010-05-03 | 2014-04-29 | Masimo Corporation | Reflective non-invasive sensor |
US9138180B1 (en) | 2010-05-03 | 2015-09-22 | Masimo Corporation | Sensor adapter cable |
US8666468B1 (en) | 2010-05-06 | 2014-03-04 | Masimo Corporation | Patient monitor for determining microcirculation state |
US20110295142A1 (en) * | 2010-05-25 | 2011-12-01 | Neurowave Systems Inc. | Detector for identifying physiological artifacts from physiological signals and method |
US9326712B1 (en) | 2010-06-02 | 2016-05-03 | Masimo Corporation | Opticoustic sensor |
US8740792B1 (en) | 2010-07-12 | 2014-06-03 | Masimo Corporation | Patient monitor capable of accounting for environmental conditions |
US9408542B1 (en) | 2010-07-22 | 2016-08-09 | Masimo Corporation | Non-invasive blood pressure measurement system |
WO2012027613A1 (en) | 2010-08-26 | 2012-03-01 | Masimo Corporation | Blood pressure measurement system |
US12198790B1 (en) | 2010-10-07 | 2025-01-14 | Masimo Corporation | Physiological monitor sensor systems and methods |
US9211095B1 (en) | 2010-10-13 | 2015-12-15 | Masimo Corporation | Physiological measurement logic engine |
US8723677B1 (en) | 2010-10-20 | 2014-05-13 | Masimo Corporation | Patient safety system with automatically adjusting bed |
US20120226117A1 (en) | 2010-12-01 | 2012-09-06 | Lamego Marcelo M | Handheld processing device including medical applications for minimally and non invasive glucose measurements |
EP3567603A1 (en) | 2011-02-13 | 2019-11-13 | Masimo Corporation | Medical risk characterization system |
US9066666B2 (en) | 2011-02-25 | 2015-06-30 | Cercacor Laboratories, Inc. | Patient monitor for monitoring microcirculation |
US8830449B1 (en) | 2011-04-18 | 2014-09-09 | Cercacor Laboratories, Inc. | Blood analysis system |
US9095316B2 (en) | 2011-04-20 | 2015-08-04 | Masimo Corporation | System for generating alarms based on alarm patterns |
US9622692B2 (en) | 2011-05-16 | 2017-04-18 | Masimo Corporation | Personal health device |
US9986919B2 (en) | 2011-06-21 | 2018-06-05 | Masimo Corporation | Patient monitoring system |
US9532722B2 (en) | 2011-06-21 | 2017-01-03 | Masimo Corporation | Patient monitoring system |
US9245668B1 (en) | 2011-06-29 | 2016-01-26 | Cercacor Laboratories, Inc. | Low noise cable providing communication between electronic sensor components and patient monitor |
US11439329B2 (en) | 2011-07-13 | 2022-09-13 | Masimo Corporation | Multiple measurement mode in a physiological sensor |
US9192351B1 (en) | 2011-07-22 | 2015-11-24 | Masimo Corporation | Acoustic respiratory monitoring sensor with probe-off detection |
US8755872B1 (en) | 2011-07-28 | 2014-06-17 | Masimo Corporation | Patient monitoring system for indicating an abnormal condition |
US9782077B2 (en) | 2011-08-17 | 2017-10-10 | Masimo Corporation | Modulated physiological sensor |
US9943269B2 (en) | 2011-10-13 | 2018-04-17 | Masimo Corporation | System for displaying medical monitoring data |
US9808188B1 (en) | 2011-10-13 | 2017-11-07 | Masimo Corporation | Robust fractional saturation determination |
EP3584799B1 (en) | 2011-10-13 | 2022-11-09 | Masimo Corporation | Medical monitoring hub |
US9778079B1 (en) | 2011-10-27 | 2017-10-03 | Masimo Corporation | Physiological monitor gauge panel |
US9445759B1 (en) | 2011-12-22 | 2016-09-20 | Cercacor Laboratories, Inc. | Blood glucose calibration system |
US12004881B2 (en) | 2012-01-04 | 2024-06-11 | Masimo Corporation | Automated condition screening and detection |
US9392945B2 (en) | 2012-01-04 | 2016-07-19 | Masimo Corporation | Automated CCHD screening and detection |
US11172890B2 (en) | 2012-01-04 | 2021-11-16 | Masimo Corporation | Automated condition screening and detection |
US9267572B2 (en) | 2012-02-08 | 2016-02-23 | Masimo Corporation | Cable tether system |
US10149616B2 (en) | 2012-02-09 | 2018-12-11 | Masimo Corporation | Wireless patient monitoring device |
US10307111B2 (en) | 2012-02-09 | 2019-06-04 | Masimo Corporation | Patient position detection system |
US9480435B2 (en) | 2012-02-09 | 2016-11-01 | Masimo Corporation | Configurable patient monitoring system |
US9195385B2 (en) | 2012-03-25 | 2015-11-24 | Masimo Corporation | Physiological monitor touchscreen interface |
EP4268712A3 (en) | 2012-04-17 | 2024-01-17 | Masimo Corporation | Hypersaturation index |
US10542903B2 (en) | 2012-06-07 | 2020-01-28 | Masimo Corporation | Depth of consciousness monitor |
US9697928B2 (en) | 2012-08-01 | 2017-07-04 | Masimo Corporation | Automated assembly sensor cable |
US10827961B1 (en) | 2012-08-29 | 2020-11-10 | Masimo Corporation | Physiological measurement calibration |
US9877650B2 (en) | 2012-09-20 | 2018-01-30 | Masimo Corporation | Physiological monitor with mobile computing device connectivity |
US9955937B2 (en) | 2012-09-20 | 2018-05-01 | Masimo Corporation | Acoustic patient sensor coupler |
US9749232B2 (en) | 2012-09-20 | 2017-08-29 | Masimo Corporation | Intelligent medical network edge router |
US9717458B2 (en) | 2012-10-20 | 2017-08-01 | Masimo Corporation | Magnetic-flap optical sensor |
US9560996B2 (en) | 2012-10-30 | 2017-02-07 | Masimo Corporation | Universal medical system |
US9787568B2 (en) | 2012-11-05 | 2017-10-10 | Cercacor Laboratories, Inc. | Physiological test credit method |
US9750461B1 (en) | 2013-01-02 | 2017-09-05 | Masimo Corporation | Acoustic respiratory monitoring sensor with probe-off detection |
US9724025B1 (en) | 2013-01-16 | 2017-08-08 | Masimo Corporation | Active-pulse blood analysis system |
US9750442B2 (en) | 2013-03-09 | 2017-09-05 | Masimo Corporation | Physiological status monitor |
US10441181B1 (en) | 2013-03-13 | 2019-10-15 | Masimo Corporation | Acoustic pulse and respiration monitoring system |
US9965946B2 (en) | 2013-03-13 | 2018-05-08 | Masimo Corporation | Systems and methods for monitoring a patient health network |
US9936917B2 (en) | 2013-03-14 | 2018-04-10 | Masimo Laboratories, Inc. | Patient monitor placement indicator |
US9986952B2 (en) | 2013-03-14 | 2018-06-05 | Masimo Corporation | Heart sound simulator |
US9474474B2 (en) | 2013-03-14 | 2016-10-25 | Masimo Corporation | Patient monitor as a minimally invasive glucometer |
WO2014150684A1 (en) * | 2013-03-15 | 2014-09-25 | Simon Adam J | Artifact as a feature in neuro diagnostics |
US10456038B2 (en) | 2013-03-15 | 2019-10-29 | Cercacor Laboratories, Inc. | Cloud-based physiological monitoring system |
US12178572B1 (en) | 2013-06-11 | 2024-12-31 | Masimo Corporation | Blood glucose sensing system |
US9891079B2 (en) | 2013-07-17 | 2018-02-13 | Masimo Corporation | Pulser with double-bearing position encoder for non-invasive physiological monitoring |
US10555678B2 (en) | 2013-08-05 | 2020-02-11 | Masimo Corporation | Blood pressure monitor with valve-chamber assembly |
WO2015038683A2 (en) | 2013-09-12 | 2015-03-19 | Cercacor Laboratories, Inc. | Medical device management system |
US10010276B2 (en) | 2013-10-07 | 2018-07-03 | Masimo Corporation | Regional oximetry user interface |
US11147518B1 (en) | 2013-10-07 | 2021-10-19 | Masimo Corporation | Regional oximetry signal processor |
US10828007B1 (en) | 2013-10-11 | 2020-11-10 | Masimo Corporation | Acoustic sensor with attachment portion |
US10832818B2 (en) | 2013-10-11 | 2020-11-10 | Masimo Corporation | Alarm notification system |
US10279247B2 (en) | 2013-12-13 | 2019-05-07 | Masimo Corporation | Avatar-incentive healthcare therapy |
US11259745B2 (en) | 2014-01-28 | 2022-03-01 | Masimo Corporation | Autonomous drug delivery system |
US10086138B1 (en) | 2014-01-28 | 2018-10-02 | Masimo Corporation | Autonomous drug delivery system |
US10532174B2 (en) | 2014-02-21 | 2020-01-14 | Masimo Corporation | Assistive capnography device |
US9924897B1 (en) | 2014-06-12 | 2018-03-27 | Masimo Corporation | Heated reprocessing of physiological sensors |
US10123729B2 (en) | 2014-06-13 | 2018-11-13 | Nanthealth, Inc. | Alarm fatigue management systems and methods |
US10231670B2 (en) | 2014-06-19 | 2019-03-19 | Masimo Corporation | Proximity sensor in pulse oximeter |
US10111591B2 (en) | 2014-08-26 | 2018-10-30 | Nanthealth, Inc. | Real-time monitoring systems and methods in a healthcare environment |
US10231657B2 (en) | 2014-09-04 | 2019-03-19 | Masimo Corporation | Total hemoglobin screening sensor |
US10383520B2 (en) | 2014-09-18 | 2019-08-20 | Masimo Semiconductor, Inc. | Enhanced visible near-infrared photodiode and non-invasive physiological sensor |
EP3247439B8 (en) | 2015-01-23 | 2021-03-03 | Masimo Corporation | Nasal/oral cannula system |
CN113054464B (en) | 2015-02-06 | 2023-04-07 | 迈心诺公司 | Connector and sensor assembly |
US10568553B2 (en) | 2015-02-06 | 2020-02-25 | Masimo Corporation | Soft boot pulse oximetry sensor |
CA2974830C (en) | 2015-02-06 | 2023-06-27 | Masimo Corporation | Fold flex circuit for lnop |
USD755392S1 (en) | 2015-02-06 | 2016-05-03 | Masimo Corporation | Pulse oximetry sensor |
US10524738B2 (en) | 2015-05-04 | 2020-01-07 | Cercacor Laboratories, Inc. | Noninvasive sensor system with visual infographic display |
WO2016191307A1 (en) | 2015-05-22 | 2016-12-01 | Cercacor Laboratories, Inc. | Non-invasive optical physiological differential pathlength sensor |
US10448871B2 (en) | 2015-07-02 | 2019-10-22 | Masimo Corporation | Advanced pulse oximetry sensor |
WO2017027621A1 (en) | 2015-08-11 | 2017-02-16 | Masimo Corporation | Medical monitoring analysis and replay including indicia responsive to light attenuated by body tissue |
KR102612874B1 (en) | 2015-08-31 | 2023-12-12 | 마시모 코오퍼레이션 | Wireless patient monitoring systems and methods |
US11504066B1 (en) | 2015-09-04 | 2022-11-22 | Cercacor Laboratories, Inc. | Low-noise sensor system |
US11679579B2 (en) | 2015-12-17 | 2023-06-20 | Masimo Corporation | Varnish-coated release liner |
US10471159B1 (en) | 2016-02-12 | 2019-11-12 | Masimo Corporation | Diagnosis, removal, or mechanical damaging of tumor using plasmonic nanobubbles |
US10806858B2 (en) | 2016-02-17 | 2020-10-20 | Zyno Medical, Llc | Automatic anesthesiology pump allowing improved anesthesiologist mobility |
US10993662B2 (en) | 2016-03-04 | 2021-05-04 | Masimo Corporation | Nose sensor |
US10537285B2 (en) | 2016-03-04 | 2020-01-21 | Masimo Corporation | Nose sensor |
US11191484B2 (en) | 2016-04-29 | 2021-12-07 | Masimo Corporation | Optical sensor tape |
WO2018009612A1 (en) | 2016-07-06 | 2018-01-11 | Patient Doctor Technologies, Inc. | Secure and zero knowledge data sharing for cloud applications |
US10617302B2 (en) | 2016-07-07 | 2020-04-14 | Masimo Corporation | Wearable pulse oximeter and respiration monitor |
CN106137187B (en) * | 2016-07-15 | 2019-01-08 | 广州视源电子科技股份有限公司 | Electroencephalogram state detection method and device |
EP3525661A1 (en) | 2016-10-13 | 2019-08-21 | Masimo Corporation | Systems and methods for patient fall detection |
GB2557199B (en) | 2016-11-30 | 2020-11-04 | Lidco Group Plc | Haemodynamic monitor with improved filtering |
US11504058B1 (en) | 2016-12-02 | 2022-11-22 | Masimo Corporation | Multi-site noninvasive measurement of a physiological parameter |
US10750984B2 (en) | 2016-12-22 | 2020-08-25 | Cercacor Laboratories, Inc. | Methods and devices for detecting intensity of light with translucent detector |
US10721785B2 (en) | 2017-01-18 | 2020-07-21 | Masimo Corporation | Patient-worn wireless physiological sensor with pairing functionality |
US10388120B2 (en) | 2017-02-24 | 2019-08-20 | Masimo Corporation | Localized projection of audible noises in medical settings |
US10327713B2 (en) | 2017-02-24 | 2019-06-25 | Masimo Corporation | Modular multi-parameter patient monitoring device |
US11024064B2 (en) | 2017-02-24 | 2021-06-01 | Masimo Corporation | Augmented reality system for displaying patient data |
EP4365911A3 (en) | 2017-02-24 | 2024-05-29 | Masimo Corporation | Medical device cable and method of sharing data between connected medical devices |
WO2018156648A1 (en) | 2017-02-24 | 2018-08-30 | Masimo Corporation | Managing dynamic licenses for physiological parameters in a patient monitoring environment |
US11086609B2 (en) | 2017-02-24 | 2021-08-10 | Masimo Corporation | Medical monitoring hub |
WO2018165618A1 (en) | 2017-03-10 | 2018-09-13 | Masimo Corporation | Pneumonia screener |
US11402906B2 (en) * | 2017-03-31 | 2022-08-02 | Agency For Science, Technology And Research | System and method for detecting eye activity |
WO2018194992A1 (en) | 2017-04-18 | 2018-10-25 | Masimo Corporation | Nose sensor |
US10918281B2 (en) | 2017-04-26 | 2021-02-16 | Masimo Corporation | Medical monitoring device having multiple configurations |
USD835285S1 (en) | 2017-04-28 | 2018-12-04 | Masimo Corporation | Medical monitoring device |
CN110891472B (en) | 2017-04-28 | 2023-04-04 | 迈心诺公司 | Spot check measuring system |
USD835283S1 (en) | 2017-04-28 | 2018-12-04 | Masimo Corporation | Medical monitoring device |
USD835282S1 (en) | 2017-04-28 | 2018-12-04 | Masimo Corporation | Medical monitoring device |
USD835284S1 (en) | 2017-04-28 | 2018-12-04 | Masimo Corporation | Medical monitoring device |
JP7159208B2 (en) | 2017-05-08 | 2022-10-24 | マシモ・コーポレイション | A system for pairing a medical system with a network controller by using a dongle |
US12207933B1 (en) * | 2017-07-10 | 2025-01-28 | Neurowave Systems Inc. | Detector for identifying physiological artifacts from physiological signals and method |
US11026604B2 (en) | 2017-07-13 | 2021-06-08 | Cercacor Laboratories, Inc. | Medical monitoring device for harmonizing physiological measurements |
USD906970S1 (en) | 2017-08-15 | 2021-01-05 | Masimo Corporation | Connector |
USD880477S1 (en) | 2017-08-15 | 2020-04-07 | Masimo Corporation | Connector |
USD890708S1 (en) | 2017-08-15 | 2020-07-21 | Masimo Corporation | Connector |
KR102611362B1 (en) | 2017-08-15 | 2023-12-08 | 마시모 코오퍼레이션 | Waterproof connector for non-invasive patient monitors |
KR20200074175A (en) | 2017-10-19 | 2020-06-24 | 마시모 코오퍼레이션 | Display configuration for medical monitoring systems |
KR20250021596A (en) | 2017-10-31 | 2025-02-13 | 마시모 코오퍼레이션 | System for Displaying Oxygen State Indications |
USD925597S1 (en) | 2017-10-31 | 2021-07-20 | Masimo Corporation | Display screen or portion thereof with graphical user interface |
US10567961B2 (en) | 2017-11-02 | 2020-02-18 | Bank Of America Corporation | System for electroencephalogram patterning recognition for authentication |
US10456054B2 (en) | 2017-11-02 | 2019-10-29 | Bank Of America Corporation | Electroencephalogram triggered resource distribution query system |
US11152086B2 (en) | 2017-11-02 | 2021-10-19 | Bank Of America Corporation | Electroencephalogram triggered experience modification system |
US11766198B2 (en) | 2018-02-02 | 2023-09-26 | Cercacor Laboratories, Inc. | Limb-worn patient monitoring device |
EP3782165A1 (en) | 2018-04-19 | 2021-02-24 | Masimo Corporation | Mobile patient alarm display |
WO2019209915A1 (en) | 2018-04-24 | 2019-10-31 | Cercacor Laboratories, Inc. | Easy insert finger sensor for transmission based spectroscopy sensor |
US10939878B2 (en) | 2018-06-06 | 2021-03-09 | Masimo Corporation | Opioid overdose monitoring |
US12097043B2 (en) | 2018-06-06 | 2024-09-24 | Masimo Corporation | Locating a locally stored medication |
US10779098B2 (en) | 2018-07-10 | 2020-09-15 | Masimo Corporation | Patient monitor alarm speaker analyzer |
US11872156B2 (en) | 2018-08-22 | 2024-01-16 | Masimo Corporation | Core body temperature measurement |
USD1041511S1 (en) | 2018-10-11 | 2024-09-10 | Masimo Corporation | Display screen or portion thereof with a graphical user interface |
CN119014866A (en) | 2018-10-11 | 2024-11-26 | 迈心诺公司 | Patient connector assembly with vertical detents |
USD998630S1 (en) | 2018-10-11 | 2023-09-12 | Masimo Corporation | Display screen or portion thereof with a graphical user interface |
USD916135S1 (en) | 2018-10-11 | 2021-04-13 | Masimo Corporation | Display screen or portion thereof with a graphical user interface |
USD999246S1 (en) | 2018-10-11 | 2023-09-19 | Masimo Corporation | Display screen or portion thereof with a graphical user interface |
USD917564S1 (en) | 2018-10-11 | 2021-04-27 | Masimo Corporation | Display screen or portion thereof with graphical user interface |
USD917550S1 (en) | 2018-10-11 | 2021-04-27 | Masimo Corporation | Display screen or portion thereof with a graphical user interface |
US11389093B2 (en) | 2018-10-11 | 2022-07-19 | Masimo Corporation | Low noise oximetry cable |
US11406286B2 (en) | 2018-10-11 | 2022-08-09 | Masimo Corporation | Patient monitoring device with improved user interface |
USD998631S1 (en) | 2018-10-11 | 2023-09-12 | Masimo Corporation | Display screen or portion thereof with a graphical user interface |
USD897098S1 (en) | 2018-10-12 | 2020-09-29 | Masimo Corporation | Card holder set |
US11272839B2 (en) | 2018-10-12 | 2022-03-15 | Ma Simo Corporation | System for transmission of sensor data using dual communication protocol |
US11464410B2 (en) | 2018-10-12 | 2022-10-11 | Masimo Corporation | Medical systems and methods |
US12004869B2 (en) | 2018-11-05 | 2024-06-11 | Masimo Corporation | System to monitor and manage patient hydration via plethysmograph variablity index in response to the passive leg raising |
US11986289B2 (en) | 2018-11-27 | 2024-05-21 | Willow Laboratories, Inc. | Assembly for medical monitoring device with multiple physiological sensors |
US11684296B2 (en) | 2018-12-21 | 2023-06-27 | Cercacor Laboratories, Inc. | Noninvasive physiological sensor |
US12066426B1 (en) | 2019-01-16 | 2024-08-20 | Masimo Corporation | Pulsed micro-chip laser for malaria detection |
WO2020163640A1 (en) | 2019-02-07 | 2020-08-13 | Masimo Corporation | Combining multiple qeeg features to estimate drug-independent sedation level using machine learning |
US12220207B2 (en) | 2019-02-26 | 2025-02-11 | Masimo Corporation | Non-contact core body temperature measurement systems and methods |
WO2020214826A1 (en) | 2019-04-17 | 2020-10-22 | Masimo Corporation | Patient monitoring systems, devices, and methods |
USD985498S1 (en) | 2019-08-16 | 2023-05-09 | Masimo Corporation | Connector |
USD921202S1 (en) | 2019-08-16 | 2021-06-01 | Masimo Corporation | Holder for a blood pressure device |
USD917704S1 (en) | 2019-08-16 | 2021-04-27 | Masimo Corporation | Patient monitor |
USD919094S1 (en) | 2019-08-16 | 2021-05-11 | Masimo Corporation | Blood pressure device |
US12207901B1 (en) | 2019-08-16 | 2025-01-28 | Masimo Corporation | Optical detection of transient vapor nanobubbles in a microfluidic device |
USD919100S1 (en) | 2019-08-16 | 2021-05-11 | Masimo Corporation | Holder for a patient monitor |
US11832940B2 (en) | 2019-08-27 | 2023-12-05 | Cercacor Laboratories, Inc. | Non-invasive medical monitoring device for blood analyte measurements |
US12131661B2 (en) | 2019-10-03 | 2024-10-29 | Willow Laboratories, Inc. | Personalized health coaching system |
USD927699S1 (en) | 2019-10-18 | 2021-08-10 | Masimo Corporation | Electrode pad |
US11803623B2 (en) | 2019-10-18 | 2023-10-31 | Masimo Corporation | Display layout and interactive objects for patient monitoring |
WO2021081404A1 (en) | 2019-10-25 | 2021-04-29 | Cercacor Laboratories, Inc. | Indicator compounds, devices comprising indicator compounds, and methods of making and using the same |
US12272445B1 (en) | 2019-12-05 | 2025-04-08 | Masimo Corporation | Automated medical coding |
KR20220129033A (en) | 2020-01-13 | 2022-09-22 | 마시모 코오퍼레이션 | Wearable device with physiological parameter monitoring function |
KR20220132615A (en) | 2020-01-30 | 2022-09-30 | 세르카코르 래버러토리즈, 인크. | Redundant Staggered Glucose Sensor Disease Management System |
US11879960B2 (en) | 2020-02-13 | 2024-01-23 | Masimo Corporation | System and method for monitoring clinical activities |
EP4104037A1 (en) | 2020-02-13 | 2022-12-21 | Masimo Corporation | System and method for monitoring clinical activities |
US12048534B2 (en) | 2020-03-04 | 2024-07-30 | Willow Laboratories, Inc. | Systems and methods for securing a tissue site to a sensor |
JP2023518303A (en) | 2020-03-20 | 2023-04-28 | マシモ・コーポレイション | Wearable device for non-invasive body temperature measurement |
USD933232S1 (en) | 2020-05-11 | 2021-10-12 | Masimo Corporation | Blood pressure monitor |
US12127838B2 (en) | 2020-04-22 | 2024-10-29 | Willow Laboratories, Inc. | Self-contained minimal action invasive blood constituent system |
USD979516S1 (en) | 2020-05-11 | 2023-02-28 | Masimo Corporation | Connector |
KR20210146723A (en) * | 2020-05-27 | 2021-12-06 | 주식회사 브레인유 | Consciousness Level Determination Method and Computer Program |
US12029844B2 (en) | 2020-06-25 | 2024-07-09 | Willow Laboratories, Inc. | Combination spirometer-inhaler |
USD974193S1 (en) | 2020-07-27 | 2023-01-03 | Masimo Corporation | Wearable temperature measurement device |
USD980091S1 (en) | 2020-07-27 | 2023-03-07 | Masimo Corporation | Wearable temperature measurement device |
US12082926B2 (en) | 2020-08-04 | 2024-09-10 | Masimo Corporation | Optical sensor with multiple detectors or multiple emitters |
WO2022040231A1 (en) | 2020-08-19 | 2022-02-24 | Masimo Corporation | Strap for a wearable device |
USD946597S1 (en) | 2020-09-30 | 2022-03-22 | Masimo Corporation | Display screen or portion thereof with graphical user interface |
USD946596S1 (en) | 2020-09-30 | 2022-03-22 | Masimo Corporation | Display screen or portion thereof with graphical user interface |
US12178852B2 (en) | 2020-09-30 | 2024-12-31 | Willow Laboratories, Inc. | Insulin formulations and uses in infusion devices |
USD946598S1 (en) | 2020-09-30 | 2022-03-22 | Masimo Corporation | Display screen or portion thereof with graphical user interface |
USD1061585S1 (en) | 2020-10-16 | 2025-02-11 | Masimo Corporation | Display screen or portion thereof with graphical user interface |
USD997365S1 (en) | 2021-06-24 | 2023-08-29 | Masimo Corporation | Physiological nose sensor |
USD1036293S1 (en) | 2021-08-17 | 2024-07-23 | Masimo Corporation | Straps for a wearable device |
US12126683B2 (en) | 2021-08-31 | 2024-10-22 | Masimo Corporation | Privacy switch for mobile communications device |
USD1000975S1 (en) | 2021-09-22 | 2023-10-10 | Masimo Corporation | Wearable temperature measurement device |
USD1048571S1 (en) | 2021-10-07 | 2024-10-22 | Masimo Corporation | Bite block |
US20230222805A1 (en) | 2022-01-11 | 2023-07-13 | Masimo Corporation | Machine learning based monitoring system |
USD1063893S1 (en) | 2022-03-11 | 2025-02-25 | Masimo Corporation | Electronic device |
USD1057160S1 (en) | 2022-03-29 | 2025-01-07 | Masimo Corporation | Electronic measurement device |
USD1057159S1 (en) | 2022-03-29 | 2025-01-07 | Masimo Corporation | Electronic measurement device |
USD1048908S1 (en) | 2022-10-04 | 2024-10-29 | Masimo Corporation | Wearable sensor |
USD1042596S1 (en) | 2022-12-12 | 2024-09-17 | Masimo Corporation | Monitoring camera |
USD1066244S1 (en) | 2023-05-11 | 2025-03-11 | Masimo Corporation | Charger |
USD1068656S1 (en) | 2023-05-11 | 2025-04-01 | Masimo Corporation | Charger |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6067467A (en) * | 1994-02-07 | 2000-05-23 | New York University | EEG operative and post-operative patient monitoring method |
US5813993A (en) * | 1996-04-05 | 1998-09-29 | Consolidated Research Of Richmond, Inc. | Alertness and drowsiness detection and tracking system |
US6230049B1 (en) * | 1999-08-13 | 2001-05-08 | Neuro Pace, Inc. | Integrated system for EEG monitoring and electrical stimulation with a multiplicity of electrodes |
-
1999
- 1999-11-02 US US09/431,632 patent/US6317627B1/en not_active Expired - Lifetime
-
2001
- 2001-11-13 US US10/007,849 patent/US20020082513A1/en not_active Abandoned
Cited By (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090143694A1 (en) * | 2000-12-07 | 2009-06-04 | Baruch Shlomo Krauss | Automated interpretive medical care system and methodology |
US20040236240A1 (en) * | 2000-12-07 | 2004-11-25 | Kraus Baruch Shlomo | Automated interpretive medical care system and methodology |
US10610110B2 (en) | 2000-12-07 | 2020-04-07 | Children's Medical Center Corporation | Automated interpretive medical care system and methodology |
US9993163B2 (en) | 2000-12-07 | 2018-06-12 | Oridion Medical 1987 Ltd. | Automated interpretive medical care system and methodology |
US9955875B2 (en) | 2000-12-07 | 2018-05-01 | Oridion Medical 1987 Ltd. | Automated interpretive medical care system and methodology |
US9895065B2 (en) | 2000-12-07 | 2018-02-20 | Children's Medical Center Corporation | Automated interpretive medical care system and methodology |
US9895066B2 (en) | 2000-12-07 | 2018-02-20 | Oridion Medical 1987 Ltd. | Automated interpretive medical care system and methodology |
US8679029B2 (en) * | 2000-12-07 | 2014-03-25 | Oridion Medical (1987) Ltd. | Automated interpretive medical care system and methodology |
US8147419B2 (en) | 2000-12-07 | 2012-04-03 | Baruch Shlomo Krauss | Automated interpretive medical care system and methodology |
US20090149723A1 (en) * | 2000-12-07 | 2009-06-11 | Baruch Shlomo Krauss | Automated interpretive medical care system and methodology |
US7654948B2 (en) | 2003-02-28 | 2010-02-02 | Consolidate Research of Richmond, Inc. | Automated insomnia treatment system |
US20040225179A1 (en) * | 2003-02-28 | 2004-11-11 | Consolidated Research Of Richmond, Inc. | Automated insomnia treatment system |
US8512221B2 (en) | 2003-02-28 | 2013-08-20 | Consolidated Research Of Richmond, Inc. | Automated treatment system for sleep |
US20100094103A1 (en) * | 2003-02-28 | 2010-04-15 | Consolidated Research Of Richmond, Inc | Automated treatment system for sleep |
US20040243017A1 (en) * | 2003-05-06 | 2004-12-02 | Elvir Causevic | Anesthesia and sedation monitoring system and method |
US20060019224A1 (en) * | 2004-07-23 | 2006-01-26 | Pics, Inc. | Insomnia assessment and treatment device and method |
US8073534B2 (en) * | 2005-05-10 | 2011-12-06 | Philip Low | Automated detection of sleep and waking states |
US20070016095A1 (en) * | 2005-05-10 | 2007-01-18 | Low Philip S | Automated detection of sleep and waking states |
US11690557B2 (en) * | 2005-05-10 | 2023-07-04 | The Salk Institute For Biological Studies Intellectual Property And Technology Transfer | Automated detection of sleep and waking states |
JP2008544772A (en) * | 2005-05-10 | 2008-12-11 | ザ サルク インスティテュート フォー バイオロジカル スタディーズ | Automatic detection of sleep and wakefulness |
JP2014176743A (en) * | 2005-05-10 | 2014-09-25 | Salk Institute For Biological Studies:The | Sleep-awake state automatic detection |
US20120029378A1 (en) * | 2005-05-10 | 2012-02-02 | Salk Institute For Biological Studies, The Intellectual Property And Technology Transfer | Automated detection of sleep and waking states |
US7428290B2 (en) | 2005-09-27 | 2008-09-23 | Ge Medical Systems Global Technology Company, Llc | X-ray CT apparatus |
US20070071160A1 (en) * | 2005-09-27 | 2007-03-29 | Akihiko Nishide | X-ray ct apparatus |
WO2007059248A2 (en) * | 2005-11-15 | 2007-05-24 | Hospira, Inc | System for monitoring and separating eeg and emg signals |
WO2007059248A3 (en) * | 2005-11-15 | 2009-04-30 | Hospira Inc | System for monitoring and separating eeg and emg signals |
US20070167694A1 (en) * | 2005-12-21 | 2007-07-19 | Everest Biomedical Instruments Co. | Integrated Portable Anesthesia and Sedation Monitoring Apparatus |
US20140228651A1 (en) * | 2005-12-21 | 2014-08-14 | Brainscope Company, Inc. | Integrated portable anesthesia and sedation monitoring apparatus |
US20070185697A1 (en) * | 2006-02-07 | 2007-08-09 | Microsoft Corporation | Using electroencephalograph signals for task classification and activity recognition |
US7580742B2 (en) * | 2006-02-07 | 2009-08-25 | Microsoft Corporation | Using electroencephalograph signals for task classification and activity recognition |
US20080317672A1 (en) * | 2007-06-20 | 2008-12-25 | The General Electric Company | Detection of anomalies in measurement of level of hypnosis |
US9398863B2 (en) * | 2007-06-20 | 2016-07-26 | General Electric Company | Detection of anomalies in measurement of level of hypnosis |
US8838198B2 (en) | 2008-11-14 | 2014-09-16 | Neuronetrix Solutions, Llc | Electrode system |
US8864702B2 (en) * | 2009-01-15 | 2014-10-21 | Hopital Foch | System for controlling means for injection of anesthetics or sedatives |
US10537677B2 (en) | 2009-01-15 | 2020-01-21 | Medsteer | System for controlling injectors of anaesthetics or sedatives with a view to inducing anaesthesia or sedation |
US20110295196A1 (en) * | 2009-01-15 | 2011-12-01 | Hopital Foch | System for controlling means for injection of anesthetics or sedatives |
DE102009053256A1 (en) * | 2009-11-06 | 2011-05-19 | Baars, Jan H., Dr. med. | Method for determining the analgesic level of a sedated or anaesthetized individual |
US8364255B2 (en) * | 2010-03-10 | 2013-01-29 | Brainscope Company, Inc. | Method and device for removing EEG artifacts |
US20110224569A1 (en) * | 2010-03-10 | 2011-09-15 | Robert Isenhart | Method and device for removing eeg artifacts |
US11717210B2 (en) | 2010-09-28 | 2023-08-08 | Masimo Corporation | Depth of consciousness monitor including oximeter |
US8821397B2 (en) | 2010-09-28 | 2014-09-02 | Masimo Corporation | Depth of consciousness monitor including oximeter |
US9775545B2 (en) | 2010-09-28 | 2017-10-03 | Masimo Corporation | Magnetic electrical connector for patient monitors |
US9538949B2 (en) | 2010-09-28 | 2017-01-10 | Masimo Corporation | Depth of consciousness monitor including oximeter |
US10531811B2 (en) | 2010-09-28 | 2020-01-14 | Masimo Corporation | Depth of consciousness monitor including oximeter |
US20140081094A1 (en) * | 2011-05-02 | 2014-03-20 | Denis Jordan | Method for consciousness and pain monitoring, module for analyzing eeg signals, and eeg anesthesia monitor |
US8666484B2 (en) | 2011-11-25 | 2014-03-04 | Persyst Development Corporation | Method and system for displaying EEG data |
US9820663B2 (en) | 2012-01-24 | 2017-11-21 | Neurovigil, Inc. | Correlating brain signal to intentional and unintentional changes in brain state |
US9364163B2 (en) | 2012-01-24 | 2016-06-14 | Neurovigil, Inc. | Correlating brain signal to intentional and unintentional changes in brain state |
CN103040459A (en) * | 2013-01-05 | 2013-04-17 | 西安交通大学 | Method of high-fidelity filtering for power frequency interferences in multichannel feeble physiological information recording system |
CN103169466A (en) * | 2013-04-01 | 2013-06-26 | 张宇奇 | Algesia monitoring system and monitoring method for anesthesia |
US9849241B2 (en) | 2013-04-24 | 2017-12-26 | Fresenius Kabi Deutschland Gmbh | Method of operating a control device for controlling an infusion device |
US10765367B2 (en) | 2014-10-07 | 2020-09-08 | Masimo Corporation | Modular physiological sensors |
US10154815B2 (en) | 2014-10-07 | 2018-12-18 | Masimo Corporation | Modular physiological sensors |
US11717218B2 (en) | 2014-10-07 | 2023-08-08 | Masimo Corporation | Modular physiological sensor |
US11723579B2 (en) | 2017-09-19 | 2023-08-15 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement |
US11717686B2 (en) | 2017-12-04 | 2023-08-08 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to facilitate learning and performance |
US11273283B2 (en) | 2017-12-31 | 2022-03-15 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to enhance emotional response |
US11318277B2 (en) | 2017-12-31 | 2022-05-03 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to enhance emotional response |
US11478603B2 (en) | 2017-12-31 | 2022-10-25 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to enhance emotional response |
US11364361B2 (en) | 2018-04-20 | 2022-06-21 | Neuroenhancement Lab, LLC | System and method for inducing sleep by transplanting mental states |
US11452839B2 (en) | 2018-09-14 | 2022-09-27 | Neuroenhancement Lab, LLC | System and method of improving sleep |
US11786694B2 (en) | 2019-05-24 | 2023-10-17 | NeuroLight, Inc. | Device, method, and app for facilitating sleep |
Also Published As
Publication number | Publication date |
---|---|
US6317627B1 (en) | 2001-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6317627B1 (en) | Anesthesia monitoring system based on electroencephalographic signals | |
US6067467A (en) | EEG operative and post-operative patient monitoring method | |
US5699808A (en) | EEG operative and post-operative patient monitoring system and method | |
US11553869B1 (en) | Multi-channel brain or cortical activity monitoring and method | |
US7711417B2 (en) | System and method for guidance of anesthesia, analgesia and amnesia | |
US6016444A (en) | Automatic control of anesthesia using quantitative EEG | |
Kane et al. | A revised glossary of terms most commonly used by clinical electroencephalographers and updated proposal for the report format of the EEG findings. Revision 2017 | |
JP5404366B2 (en) | Method and apparatus for monitoring consciousness | |
EP1757226B1 (en) | Measurement of responsiveness of a patient under anaesthesia | |
US7625340B2 (en) | Identification of a dominant signal component in a biosignal | |
EP1854404B1 (en) | Monitoring of the state of the central nervous system of a subject | |
EP1250886B1 (en) | Anesthesia monitoring system based on electroencephalographic signals | |
Mccarron | Psychophysiological discriminants of reactive depression | |
Hasan et al. | Validation of computer analysed polygraphic patterns during drowsiness and sleep onset | |
Akay et al. | Reduced respiratory-related evoked activity in subjects with obstructive sleep apnea syndrome | |
Tasker et al. | The cerebral function analysing monitor in paediatric medical intensive care: applications and limitations | |
Joysly et al. | Abnormality recognition during drowsy state from ECG and EEG | |
Cvetkovic et al. | Sleep onset estimator: evaluation of parameters | |
Lonishin | EEG changes and C-Trend parameters in healthy patients during induction of anesthesia | |
Kane et al. | Clinical Neurophysiology Practice | |
Imhoff | Correlation between the EEG monitors BIS and State entropy and their performance in differentiate consciousness and unconsciousness-an EEG Reanalysis | |
TWM451978U (en) | Multi anesthesia depth signal measuring device | |
Duntley et al. | Failure of tracheostomy treatment of the obstructive sleep appnea syndrome |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE |